Likelike的个人主页 - 老虎社区

Likelike

Likelike

Like like

IP属地：未知

93关注

29粉丝

0主题

0勋章

2021-08-28

when bitcoin rise back to $60k????

Crypto stocks surged in morning trading<blockquote>加密货币股票早盘飙升</blockquote>

2021-09-30

Nio to the multiverse moons yeah...

抱歉，原内容已删除

2021-09-14

still dun understand about hype on Nikola[疑问]

EV stocks rose in morning trading<blockquote>电动汽车股早盘上涨</blockquote>

2021-09-14

ford should be a $15 share..i wish

Ford Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer<blockquote>福特汽车表示迈克·阿门德(Mike Amend)今天加入福特，担任新任首席数字和信息官</blockquote>

2021-09-04

$NIO Inc.(NIO)$hope to reach half Tesla price haha

2021-11-13

Pfizer the old giant ,time to wake upupup...i wish...like like

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>

2021-09-23

Pfizer can reach $50 by Oct....i wish

Despite Vaccine Uncertainty, Pfizer Is a Buy<blockquote>尽管疫苗存在不确定性，辉瑞仍值得买入</blockquote>

2021-09-22

Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....

抱歉，原内容已删除

2021-08-28

when nio xpeng rise to$50???

抱歉，原内容已删除

2021-12-11

calm before the tsunami...i wish...like like

Sea Ltd stock dropped more than 5% in morning trading<blockquote>Sea Ltd股价早盘下跌超过5%</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4091708143350050","uuid":"4091708143350050","gmtCreate":1628605862019,"gmtModify":1632926032280,"name":"Likelike","pinyin":"likelike","introduction":"","introductionEn":null,"signature":"Like like","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":29,"headSize":93,"tweetSize":42,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"80.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":605437594,"gmtCreate":1639212100832,"gmtModify":1639212101161,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"calm before the tsunami...i wish...like like","listText":"calm before the tsunami...i wish...like like","text":"calm before the tsunami...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605437594","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://www.laohu8.com/m/news/1133027099?lang=zh_CN&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading<blockquote>Sea Ltd股价早盘下跌超过5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p><p><blockquote>Sea Ltd股价早盘下跌超过5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading<blockquote>Sea Ltd股价早盘下跌超过5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading<blockquote>Sea Ltd股价早盘下跌超过5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-11 00:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p><p><blockquote>Sea Ltd股价早盘下跌超过5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":3159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609255210,"gmtCreate":1638287916044,"gmtModify":1638287916186,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Apple rise a day keep the shorters away...i wish..like like","listText":"Apple rise a day keep the shorters away...i wish..like like","text":"Apple rise a day keep the shorters away...i wish..like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609255210","repostId":"1158390889","repostType":4,"repost":{"id":"1158390889","kind":"news","pubTimestamp":1638285505,"share":"https://www.laohu8.com/m/news/1158390889?lang=zh_CN&edition=full","pubTime":"2021-11-30 23:18","market":"us","language":"en","title":"Apple Stock: What to Expect During the Holiday Season<blockquote>苹果股票：假期期间的预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158390889","media":"TheStreet","summary":"The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.Black Friday and Cyber Monday are behind us. With that, the 2021 holiday season in the US and parts of the world has officially begun. Consumer product and service companies like Apple are staring into the busiest weeks of sales in the year.Figure 1: Apple's iPhone, Apple Watch and Air Pods boxes.Today, the Apple Maven talks about what A","content":"<p>The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.</p><p><blockquote>2021年假日购物季正式开启。以下是苹果投资者在未来几周内对库比蒂诺公司及其股票的预期。</blockquote></p><p> Black Friday and Cyber Monday are behind us. With that, the 2021 holiday season in the US and parts of the world has officially begun. Consumer product and service companies like Apple are staring into the busiest weeks of sales in the year.</p><p><blockquote>黑色星期五和网络星期一已经过去了。至此，美国和世界部分地区的2021年假期正式开始。像苹果这样的消费品和服务公司正面临一年中销售最繁忙的几周。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/84c9d46c1a03b350ba81dcd1e6e39c83\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple's iPhone, Apple Watch and Air Pods boxes.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果的iPhone、苹果手表和Air Pods盒子。</span></p></blockquote></p><p> Today, the Apple Maven talks about what Apple stock&nbsp;investors should think about as the shopping season kicks into gear.</p><p><blockquote>今天，这位苹果专家谈论了随着购物季的到来，苹果股票投资者应该思考什么。</blockquote></p><p> <b>Apple to benefit from strong consumer</b></p><p><blockquote><b>苹果将受益于强劲的消费者</b></blockquote></p><p> At the highest level possible, Apple is likely to benefit from a rising tide that lifts all boats in 2021. The chart below clearly shows that consumer spending in the US has not only recovered from the 2020 flash recession, but it has been “making up for lost time”. Spending trends have even accelerated slightly compared to the pre-pandemic period.</p><p><blockquote>在可能的最高水平上，苹果可能会受益于2021年的涨潮。下图清楚地表明，美国的消费者支出不仅从2020年的快速衰退中恢复过来，而且一直在“弥补失去的时间”。与疫情之前相比，支出趋势甚至略有加速。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/edfb88f466fa1cfe1c35bddbd1cf1bb7\" tg-width=\"756\" tg-height=\"357\" width=\"100%\" height=\"auto\"><span>Figure 2: Consumer spending in US.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：美国消费者支出。</span></p></blockquote></p><p> Regarding the holiday period, however, consumer product and service sales may look a bit atypical. Adobe has recently&nbsp;reported&nbsp;that Black Friday activity online dropped year-over-year for the first time ever. Online sales reached $8.9 billion, lower than 2020’s $9 billion.</p><p><blockquote>然而，就假期而言，消费品和服务销售可能看起来有点不寻常。Adobe最近报告称，黑色星期五在线活动首次同比下降。在线销售额达到89亿美元，低于2020年的90亿美元。</blockquote></p><p> Without context, these numbers may look concerning. But once again, there is nothing typical about this COVID-19 crisis. Black Friday likely suffered from (1) consumers buying earlier than usual, to avoid delayed deliveries in late November and December, and (2) supply chain constraints causing shortages and missed sales opportunities.</p><p><blockquote>如果没有背景，这些数字可能看起来令人担忧。但同样，这场新冠肺炎危机没有任何典型之处。黑色星期五可能受到以下影响：(1)消费者比平时更早购买，以避免11月底和12月的延迟交货，以及(2)供应链限制导致短缺和错失销售机会。</blockquote></p><p> <b>Apple could do better than average</b></p><p><blockquote><b>苹果可以做得比平均水平更好</b></blockquote></p><p> The demand scenario described above is at least modestly optimistic, in my view, even if not without challenges on the supply side. Even so, I think that Apple has a good chance of performing better than average in the next few weeks.</p><p><blockquote>在我看来，上述需求情景至少是适度乐观的，即使供应方面并非没有挑战。即便如此，我认为苹果在未来几周的表现很有可能好于平均水平。</blockquote></p><p> For starters, the Cupertino company is&nbsp;one of the best in the world at managing inventory&nbsp;and supply chain. Consider, however, that CEO Tim Cook&nbsp;has already warned of an impact&nbsp;of $6 billion to revenues in the holiday quarter caused by the production and logistics bottlenecks.</p><p><blockquote>首先，库比蒂诺公司是世界上管理库存和供应链最好的公司之一。然而，首席执行官蒂姆·库克已经警告称，生产和物流瓶颈将对假日季度的收入造成60亿美元的影响。</blockquote></p><p> Second, the demand for Apple’s products and services seems unshaken.I have discussed a few times that the iPhone, for example, is likely to have its best years of sales ever in fiscal 2021 and 2022. Not even the tough comps introduced by the first 5G-capable model will likely be enough to steal the thunder of a well-received iPhone 13.</p><p><blockquote>其次，对苹果产品和服务的需求似乎没有动摇。例如，我曾多次讨论过iPhone可能会在2021财年和2022财年迎来有史以来销量最好的年份。即使是第一款支持5G的机型推出的强硬竞争也可能不足以抢走广受好评的iPhone 13的风头。</blockquote></p><p> <b>But how about AAPL stock?</b></p><p><blockquote><b>但苹果公司的股票怎么样？</b></blockquote></p><p> Keep in mind that financial performance, especially in the short term, does not always correlate with share price movements. In fact, any impact that the holiday P&amp;L results may have on Apple stock would likely not happen until late January 2022, when the company reports fiscal Q1 earnings.</p><p><blockquote>请记住，财务业绩，尤其是短期业绩，并不总是与股价变动相关。事实上，假日损益结果可能对苹果股票产生的任何影响可能要到2022年1月下旬该公司报告第一财季收益时才会发生。</blockquote></p><p> For the immediate term, Apple investors should keep in mind that the stock’s&nbsp;seasonal patterns have been historically unfavorable&nbsp;around this time of the year. The chart below shows that AAPL has clearly underperformed in November through January. Will this time be any different? Only time will tell.</p><p><blockquote>就近期而言，苹果投资者应记住，该股的季节性模式在每年的这个时候历来都是不利的。下图显示，AAPL从11月到1月的表现明显不佳。这次会有什么不同吗？只有时间能证明一切。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a4c72a2f9720f472ceba32b24f4a2a78\" tg-width=\"682\" tg-height=\"357\" width=\"100%\" height=\"auto\"><span>Figure 3: AAPL average monthly return since iPhone launch.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图3：自iPhone推出以来AAPL的平均月回报率。</span></p></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: What to Expect During the Holiday Season<blockquote>苹果股票：假期期间的预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: What to Expect During the Holiday Season<blockquote>苹果股票：假期期间的预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-11-30 23:18</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.</p><p><blockquote>2021年假日购物季正式开启。以下是苹果投资者在未来几周内对库比蒂诺公司及其股票的预期。</blockquote></p><p> Black Friday and Cyber Monday are behind us. With that, the 2021 holiday season in the US and parts of the world has officially begun. Consumer product and service companies like Apple are staring into the busiest weeks of sales in the year.</p><p><blockquote>黑色星期五和网络星期一已经过去了。至此，美国和世界部分地区的2021年假期正式开始。像苹果这样的消费品和服务公司正面临一年中销售最繁忙的几周。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/84c9d46c1a03b350ba81dcd1e6e39c83\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple's iPhone, Apple Watch and Air Pods boxes.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果的iPhone、苹果手表和Air Pods盒子。</span></p></blockquote></p><p> Today, the Apple Maven talks about what Apple stock&nbsp;investors should think about as the shopping season kicks into gear.</p><p><blockquote>今天，这位苹果专家谈论了随着购物季的到来，苹果股票投资者应该思考什么。</blockquote></p><p> <b>Apple to benefit from strong consumer</b></p><p><blockquote><b>苹果将受益于强劲的消费者</b></blockquote></p><p> At the highest level possible, Apple is likely to benefit from a rising tide that lifts all boats in 2021. The chart below clearly shows that consumer spending in the US has not only recovered from the 2020 flash recession, but it has been “making up for lost time”. Spending trends have even accelerated slightly compared to the pre-pandemic period.</p><p><blockquote>在可能的最高水平上，苹果可能会受益于2021年的涨潮。下图清楚地表明，美国的消费者支出不仅从2020年的快速衰退中恢复过来，而且一直在“弥补失去的时间”。与疫情之前相比，支出趋势甚至略有加速。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/edfb88f466fa1cfe1c35bddbd1cf1bb7\" tg-width=\"756\" tg-height=\"357\" width=\"100%\" height=\"auto\"><span>Figure 2: Consumer spending in US.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：美国消费者支出。</span></p></blockquote></p><p> Regarding the holiday period, however, consumer product and service sales may look a bit atypical. Adobe has recently&nbsp;reported&nbsp;that Black Friday activity online dropped year-over-year for the first time ever. Online sales reached $8.9 billion, lower than 2020’s $9 billion.</p><p><blockquote>然而，就假期而言，消费品和服务销售可能看起来有点不寻常。Adobe最近报告称，黑色星期五在线活动首次同比下降。在线销售额达到89亿美元，低于2020年的90亿美元。</blockquote></p><p> Without context, these numbers may look concerning. But once again, there is nothing typical about this COVID-19 crisis. Black Friday likely suffered from (1) consumers buying earlier than usual, to avoid delayed deliveries in late November and December, and (2) supply chain constraints causing shortages and missed sales opportunities.</p><p><blockquote>如果没有背景，这些数字可能看起来令人担忧。但同样，这场新冠肺炎危机没有任何典型之处。黑色星期五可能受到以下影响：(1)消费者比平时更早购买，以避免11月底和12月的延迟交货，以及(2)供应链限制导致短缺和错失销售机会。</blockquote></p><p> <b>Apple could do better than average</b></p><p><blockquote><b>苹果可以做得比平均水平更好</b></blockquote></p><p> The demand scenario described above is at least modestly optimistic, in my view, even if not without challenges on the supply side. Even so, I think that Apple has a good chance of performing better than average in the next few weeks.</p><p><blockquote>在我看来，上述需求情景至少是适度乐观的，即使供应方面并非没有挑战。即便如此，我认为苹果在未来几周的表现很有可能好于平均水平。</blockquote></p><p> For starters, the Cupertino company is&nbsp;one of the best in the world at managing inventory&nbsp;and supply chain. Consider, however, that CEO Tim Cook&nbsp;has already warned of an impact&nbsp;of $6 billion to revenues in the holiday quarter caused by the production and logistics bottlenecks.</p><p><blockquote>首先，库比蒂诺公司是世界上管理库存和供应链最好的公司之一。然而，首席执行官蒂姆·库克已经警告称，生产和物流瓶颈将对假日季度的收入造成60亿美元的影响。</blockquote></p><p> Second, the demand for Apple’s products and services seems unshaken.I have discussed a few times that the iPhone, for example, is likely to have its best years of sales ever in fiscal 2021 and 2022. Not even the tough comps introduced by the first 5G-capable model will likely be enough to steal the thunder of a well-received iPhone 13.</p><p><blockquote>其次，对苹果产品和服务的需求似乎没有动摇。例如，我曾多次讨论过iPhone可能会在2021财年和2022财年迎来有史以来销量最好的年份。即使是第一款支持5G的机型推出的强硬竞争也可能不足以抢走广受好评的iPhone 13的风头。</blockquote></p><p> <b>But how about AAPL stock?</b></p><p><blockquote><b>但苹果公司的股票怎么样？</b></blockquote></p><p> Keep in mind that financial performance, especially in the short term, does not always correlate with share price movements. In fact, any impact that the holiday P&amp;L results may have on Apple stock would likely not happen until late January 2022, when the company reports fiscal Q1 earnings.</p><p><blockquote>请记住，财务业绩，尤其是短期业绩，并不总是与股价变动相关。事实上，假日损益结果可能对苹果股票产生的任何影响可能要到2022年1月下旬该公司报告第一财季收益时才会发生。</blockquote></p><p> For the immediate term, Apple investors should keep in mind that the stock’s&nbsp;seasonal patterns have been historically unfavorable&nbsp;around this time of the year. The chart below shows that AAPL has clearly underperformed in November through January. Will this time be any different? Only time will tell.</p><p><blockquote>就近期而言，苹果投资者应记住，该股的季节性模式在每年的这个时候历来都是不利的。下图显示，AAPL从11月到1月的表现明显不佳。这次会有什么不同吗？只有时间能证明一切。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a4c72a2f9720f472ceba32b24f4a2a78\" tg-width=\"682\" tg-height=\"357\" width=\"100%\" height=\"auto\"><span>Figure 3: AAPL average monthly return since iPhone launch.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图3：自iPhone推出以来AAPL的平均月回报率。</span></p></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/stock/apple-stock-holiday-season-starts-what-next\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/apple-stock-holiday-season-starts-what-next","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158390889","content_text":"The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.\nBlack Friday and Cyber Monday are behind us. With that, the 2021 holiday season in the US and parts of the world has officially begun. Consumer product and service companies like Apple are staring into the busiest weeks of sales in the year.\nFigure 1: Apple's iPhone, Apple Watch and Air Pods boxes.\nToday, the Apple Maven talks about what Apple stock investors should think about as the shopping season kicks into gear.\nApple to benefit from strong consumer\nAt the highest level possible, Apple is likely to benefit from a rising tide that lifts all boats in 2021. The chart below clearly shows that consumer spending in the US has not only recovered from the 2020 flash recession, but it has been “making up for lost time”. Spending trends have even accelerated slightly compared to the pre-pandemic period.\nFigure 2: Consumer spending in US.\nRegarding the holiday period, however, consumer product and service sales may look a bit atypical. Adobe has recently reported that Black Friday activity online dropped year-over-year for the first time ever. Online sales reached $8.9 billion, lower than 2020’s $9 billion.\nWithout context, these numbers may look concerning. But once again, there is nothing typical about this COVID-19 crisis. Black Friday likely suffered from (1) consumers buying earlier than usual, to avoid delayed deliveries in late November and December, and (2) supply chain constraints causing shortages and missed sales opportunities.\nApple could do better than average\nThe demand scenario described above is at least modestly optimistic, in my view, even if not without challenges on the supply side. Even so, I think that Apple has a good chance of performing better than average in the next few weeks.\nFor starters, the Cupertino company is one of the best in the world at managing inventory and supply chain. Consider, however, that CEO Tim Cook has already warned of an impact of $6 billion to revenues in the holiday quarter caused by the production and logistics bottlenecks.\nSecond, the demand for Apple’s products and services seems unshaken.I have discussed a few times that the iPhone, for example, is likely to have its best years of sales ever in fiscal 2021 and 2022. Not even the tough comps introduced by the first 5G-capable model will likely be enough to steal the thunder of a well-received iPhone 13.\nBut how about AAPL stock?\nKeep in mind that financial performance, especially in the short term, does not always correlate with share price movements. In fact, any impact that the holiday P&L results may have on Apple stock would likely not happen until late January 2022, when the company reports fiscal Q1 earnings.\nFor the immediate term, Apple investors should keep in mind that the stock’s seasonal patterns have been historically unfavorable around this time of the year. The chart below shows that AAPL has clearly underperformed in November through January. Will this time be any different? Only time will tell.\nFigure 3: AAPL average monthly return since iPhone launch.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":4306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878374879,"gmtCreate":1637155859042,"gmtModify":1637155859205,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Hope the new CFO can create breaking amazing accounting...i wish.. like like","listText":"Hope the new CFO can create breaking amazing accounting...i wish.. like like","text":"Hope the new CFO can create breaking amazing accounting...i wish.. like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878374879","repostId":"1174626804","repostType":4,"repost":{"id":"1174626804","kind":"news","pubTimestamp":1637151624,"share":"https://www.laohu8.com/m/news/1174626804?lang=zh_CN&edition=full","pubTime":"2021-11-17 20:20","market":"us","language":"en","title":"Pfizer CFO Frank D'Amelio to retire<blockquote>辉瑞首席财务官弗兰克·达梅里奥将退休</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174626804","media":"Reuters","summary":"Pfizer Inc(PFE.N)said on Wednesday Chief Financial Officer and executive vice president of global su","content":"<p>Pfizer Inc(PFE.N)said on Wednesday Chief Financial Officer and executive vice president of global supply Frank D'Amelio will retire after nearly 15 years at the company.</p><p><blockquote>辉瑞公司（PFE.N）周三表示，首席财务官兼全球供应执行副总裁Frank D’Amelio将在公司工作近15年后退休。</blockquote></p><p> The drugmaker said it has started an external search for D'Amelio's successor.</p><p><blockquote>该制药商表示，已开始在外部寻找达梅里奥的继任者。</blockquote></p><p> During his tenure as CFO, D'Amelio, 63, oversaw the divestitures of Pfizer's animal health, consumer health and mature products businesses and led multiple acquisitions and partnerships valued at nearly $200 billion.</p><p><blockquote>63岁的达梅里奥在担任首席财务官期间，负责监督辉瑞动物健康、消费者健康和成熟产品业务的剥离，并领导了价值近2000亿美元的多项收购和合作伙伴关系。</blockquote></p><p> The company said Mike McDermott, who headed the production and supply of Pfizer's COVID-19 vaccine, will take the role of executive vice president, chief global supply officer.</p><p><blockquote>该公司表示，负责辉瑞COVID-19疫苗生产和供应的迈克·麦克德莫特(Mike McDermott)将担任执行副总裁兼首席全球供应官。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer CFO Frank D'Amelio to retire<blockquote>辉瑞首席财务官弗兰克·达梅里奥将退休</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer CFO Frank D'Amelio to retire<blockquote>辉瑞首席财务官弗兰克·达梅里奥将退休</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-17 20:20</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer Inc(PFE.N)said on Wednesday Chief Financial Officer and executive vice president of global supply Frank D'Amelio will retire after nearly 15 years at the company.</p><p><blockquote>辉瑞公司（PFE.N）周三表示，首席财务官兼全球供应执行副总裁Frank D’Amelio将在公司工作近15年后退休。</blockquote></p><p> The drugmaker said it has started an external search for D'Amelio's successor.</p><p><blockquote>该制药商表示，已开始在外部寻找达梅里奥的继任者。</blockquote></p><p> During his tenure as CFO, D'Amelio, 63, oversaw the divestitures of Pfizer's animal health, consumer health and mature products businesses and led multiple acquisitions and partnerships valued at nearly $200 billion.</p><p><blockquote>63岁的达梅里奥在担任首席财务官期间，负责监督辉瑞动物健康、消费者健康和成熟产品业务的剥离，并领导了价值近2000亿美元的多项收购和合作伙伴关系。</blockquote></p><p> The company said Mike McDermott, who headed the production and supply of Pfizer's COVID-19 vaccine, will take the role of executive vice president, chief global supply officer.</p><p><blockquote>该公司表示，负责辉瑞COVID-19疫苗生产和供应的迈克·麦克德莫特(Mike McDermott)将担任执行副总裁兼首席全球供应官。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-cfo-frank-damelio-retire-2021-11-17/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-cfo-frank-damelio-retire-2021-11-17/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174626804","content_text":"Pfizer Inc(PFE.N)said on Wednesday Chief Financial Officer and executive vice president of global supply Frank D'Amelio will retire after nearly 15 years at the company.\nThe drugmaker said it has started an external search for D'Amelio's successor.\nDuring his tenure as CFO, D'Amelio, 63, oversaw the divestitures of Pfizer's animal health, consumer health and mature products businesses and led multiple acquisitions and partnerships valued at nearly $200 billion.\nThe company said Mike McDermott, who headed the production and supply of Pfizer's COVID-19 vaccine, will take the role of executive vice president, chief global supply officer.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879786388,"gmtCreate":1636773154807,"gmtModify":1636773154970,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer the old giant ,time to wake upupup...i wish...like like","listText":"Pfizer the old giant ,time to wake upupup...i wish...like like","text":"Pfizer the old giant ,time to wake upupup...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/879786388","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2673,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845725320,"gmtCreate":1636370468073,"gmtModify":1636370468481,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"nio pls niu niu(bull bull)...like like","listText":"nio pls niu niu(bull bull)...like like","text":"nio pls niu niu(bull bull)...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845725320","repostId":"1103591841","repostType":4,"repost":{"id":"1103591841","kind":"news","pubTimestamp":1636363932,"share":"https://www.laohu8.com/m/news/1103591841?lang=zh_CN&edition=full","pubTime":"2021-11-08 17:32","market":"us","language":"en","title":"NIO share price on watch ahead of Q3 earnings<blockquote>蔚来股价在第三季度财报公布前值得关注</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1103591841","media":"IG","summary":"When does NIO report earnings?\nNIOis set to release its quarter three (Q3) financial results on 9 No","content":"<p>When does NIO report earnings?</p><p><blockquote>蔚来什么时候报告收益？</blockquote></p><p> NIOis set to release its quarter three (Q3) financial results on 9 November 2021, after market closes.</p><p><blockquote>NIOis将于2021年11月9日收盘后发布第三季度(Q3)财务业绩。</blockquote></p><p> NIO earnings – what to expect</p><p><blockquote>蔚来盈利——期待什么</blockquote></p><p> Current expectations are for NIO’s upcoming Q3 revenue to come in at RMB 9.3 billion, a 106% increase year-on-year (YoY) and a 10.3% increase quarter-on-quarter. Overall net loss is expected to shrink to RMB 726 million from RMB 996 a year ago, with an improvement in overall margins.</p><p><blockquote>目前预计蔚来即将到来的第三季度营收为93亿元人民币，同比增长106%，环比增长10.3%。整体净亏损预计将从一年前的9.96元人民币缩小至7.26亿元人民币，整体利润率有所改善。</blockquote></p><p> The ongoing growth momentum for the upcoming quarter may have been reflected in its vehicle deliveries for July-September, where total deliveries for that period saw an increase of 11.6% since quarter two (Q2). October’s delivery numbers may be in focus, where the restructuring of manufacturing lines and preparation for introduction of new products have led to a sharp dip in production. While the impact may not be reflected in the upcoming Q3 results, markets may look out for guidance pertaining to the resumption of production in the upcoming earnings call.</p><p><blockquote>下一季度的持续增长势头可能已经反映在7月至9月的汽车交付量上，该期间的总交付量自第二季度（Q2）以来增长了11.6%。10月份的交付数据可能是焦点，生产线的重组和新产品推出的准备导致产量急剧下降。虽然这种影响可能不会反映在即将到来的第三季度业绩中，但市场可能会在即将到来的盈利看涨期权中寻找与恢复生产相关的指导。</blockquote></p><p> As the issues seem temporary, some focus may be on overall demand for NIO’s vehicles, which has remained robust with new orders reaching another all-time high in October.</p><p><blockquote>由于这些问题似乎是暂时的，一些人可能会关注对蔚来汽车的整体需求，该需求仍然强劲，10月份新订单再创历史新高。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e8f2bf368ae683763e8c36519a1bee6f\" tg-width=\"943\" tg-height=\"589\" width=\"100%\" height=\"auto\"><span>Source: NIO</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：蔚来</span></p></blockquote></p><p> In line with global supply chain issues, NIO’s production capacity remained capped by shortages of input components, such as semiconductors. A key risk that may further aggravate production capacity ahead may be the recentCovid-19resurgences in China. With China’s zero Covid-19 stance, aggressive measures have previously disrupted production for NIO’s partners located in high-risk areas. With that, markets will be on watch for any guidance from management regarding the supply chain situation, alongside the potential impact from recent Covid-19 risks.</p><p><blockquote>根据全球供应链问题，蔚来的产能仍然受到半导体等输入零部件短缺的限制。未来可能进一步恶化产能的一个关键风险可能是中国最近的COVID-19死灰复燃。由于中国的零Covid-19立场，激进的措施此前已经扰乱了蔚来位于高风险地区的合作伙伴的生产。因此，市场将密切关注管理层关于供应链状况的任何指导，以及近期Covid-19风险的潜在影响。</blockquote></p><p> Growth catalysts for share price may include a list of three new product launches next year, which includes the NIO ET7. As the specific timing and pricing for the other two products have not been laid out yet, this will also remain in focus for the upcoming results.</p><p><blockquote>股价增长的催化剂可能包括明年推出的三款新产品，其中包括蔚来ET7。由于其他两款产品的具体时间和定价尚未公布，因此这也将继续成为即将公布的结果的焦点。</blockquote></p><p> Currently, the stock has 26 ‘buy’ recommendations, four ‘holds’ and one ‘sells’. The Bloomberg 12-month consensus target price of $59.00 suggests a potential 16.3% upside from the price at the time of writing.</p><p><blockquote>目前，该股有26条“买入”建议、4条“持有”建议和1条“卖出”建议。彭博12个月一致目标价为59.00美元，表明较撰写本文时的价格有16.3%的潜在上涨空间。</blockquote></p><p></p>","source":"lsy1627281591670","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO share price on watch ahead of Q3 earnings<blockquote>蔚来股价在第三季度财报公布前值得关注</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO share price on watch ahead of Q3 earnings<blockquote>蔚来股价在第三季度财报公布前值得关注</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">IG</strong><span class=\"h-time small\">2021-11-08 17:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>When does NIO report earnings?</p><p><blockquote>蔚来什么时候报告收益？</blockquote></p><p> NIOis set to release its quarter three (Q3) financial results on 9 November 2021, after market closes.</p><p><blockquote>NIOis将于2021年11月9日收盘后发布第三季度(Q3)财务业绩。</blockquote></p><p> NIO earnings – what to expect</p><p><blockquote>蔚来盈利——期待什么</blockquote></p><p> Current expectations are for NIO’s upcoming Q3 revenue to come in at RMB 9.3 billion, a 106% increase year-on-year (YoY) and a 10.3% increase quarter-on-quarter. Overall net loss is expected to shrink to RMB 726 million from RMB 996 a year ago, with an improvement in overall margins.</p><p><blockquote>目前预计蔚来即将到来的第三季度营收为93亿元人民币，同比增长106%，环比增长10.3%。整体净亏损预计将从一年前的9.96元人民币缩小至7.26亿元人民币，整体利润率有所改善。</blockquote></p><p> The ongoing growth momentum for the upcoming quarter may have been reflected in its vehicle deliveries for July-September, where total deliveries for that period saw an increase of 11.6% since quarter two (Q2). October’s delivery numbers may be in focus, where the restructuring of manufacturing lines and preparation for introduction of new products have led to a sharp dip in production. While the impact may not be reflected in the upcoming Q3 results, markets may look out for guidance pertaining to the resumption of production in the upcoming earnings call.</p><p><blockquote>下一季度的持续增长势头可能已经反映在7月至9月的汽车交付量上，该期间的总交付量自第二季度（Q2）以来增长了11.6%。10月份的交付数据可能是焦点，生产线的重组和新产品推出的准备导致产量急剧下降。虽然这种影响可能不会反映在即将到来的第三季度业绩中，但市场可能会在即将到来的盈利看涨期权中寻找与恢复生产相关的指导。</blockquote></p><p> As the issues seem temporary, some focus may be on overall demand for NIO’s vehicles, which has remained robust with new orders reaching another all-time high in October.</p><p><blockquote>由于这些问题似乎是暂时的，一些人可能会关注对蔚来汽车的整体需求，该需求仍然强劲，10月份新订单再创历史新高。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e8f2bf368ae683763e8c36519a1bee6f\" tg-width=\"943\" tg-height=\"589\" width=\"100%\" height=\"auto\"><span>Source: NIO</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：蔚来</span></p></blockquote></p><p> In line with global supply chain issues, NIO’s production capacity remained capped by shortages of input components, such as semiconductors. A key risk that may further aggravate production capacity ahead may be the recentCovid-19resurgences in China. With China’s zero Covid-19 stance, aggressive measures have previously disrupted production for NIO’s partners located in high-risk areas. With that, markets will be on watch for any guidance from management regarding the supply chain situation, alongside the potential impact from recent Covid-19 risks.</p><p><blockquote>根据全球供应链问题，蔚来的产能仍然受到半导体等输入零部件短缺的限制。未来可能进一步恶化产能的一个关键风险可能是中国最近的COVID-19死灰复燃。由于中国的零Covid-19立场，激进的措施此前已经扰乱了蔚来位于高风险地区的合作伙伴的生产。因此，市场将密切关注管理层关于供应链状况的任何指导，以及近期Covid-19风险的潜在影响。</blockquote></p><p> Growth catalysts for share price may include a list of three new product launches next year, which includes the NIO ET7. As the specific timing and pricing for the other two products have not been laid out yet, this will also remain in focus for the upcoming results.</p><p><blockquote>股价增长的催化剂可能包括明年推出的三款新产品，其中包括蔚来ET7。由于其他两款产品的具体时间和定价尚未公布，因此这也将继续成为即将公布的结果的焦点。</blockquote></p><p> Currently, the stock has 26 ‘buy’ recommendations, four ‘holds’ and one ‘sells’. The Bloomberg 12-month consensus target price of $59.00 suggests a potential 16.3% upside from the price at the time of writing.</p><p><blockquote>目前，该股有26条“买入”建议、4条“持有”建议和1条“卖出”建议。彭博12个月一致目标价为59.00美元，表明较撰写本文时的价格有16.3%的潜在上涨空间。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.ig.com/en-ch/news-and-trade-ideas/nio-share-price-on-watch-ahead-of-q3-earnings-211103\">IG</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://www.ig.com/en-ch/news-and-trade-ideas/nio-share-price-on-watch-ahead-of-q3-earnings-211103","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103591841","content_text":"When does NIO report earnings?\nNIOis set to release its quarter three (Q3) financial results on 9 November 2021, after market closes.\nNIO earnings – what to expect\nCurrent expectations are for NIO’s upcoming Q3 revenue to come in at RMB 9.3 billion, a 106% increase year-on-year (YoY) and a 10.3% increase quarter-on-quarter. Overall net loss is expected to shrink to RMB 726 million from RMB 996 a year ago, with an improvement in overall margins.\nThe ongoing growth momentum for the upcoming quarter may have been reflected in its vehicle deliveries for July-September, where total deliveries for that period saw an increase of 11.6% since quarter two (Q2). October’s delivery numbers may be in focus, where the restructuring of manufacturing lines and preparation for introduction of new products have led to a sharp dip in production. While the impact may not be reflected in the upcoming Q3 results, markets may look out for guidance pertaining to the resumption of production in the upcoming earnings call.\nAs the issues seem temporary, some focus may be on overall demand for NIO’s vehicles, which has remained robust with new orders reaching another all-time high in October.\nSource: NIO\nIn line with global supply chain issues, NIO’s production capacity remained capped by shortages of input components, such as semiconductors. A key risk that may further aggravate production capacity ahead may be the recentCovid-19resurgences in China. With China’s zero Covid-19 stance, aggressive measures have previously disrupted production for NIO’s partners located in high-risk areas. With that, markets will be on watch for any guidance from management regarding the supply chain situation, alongside the potential impact from recent Covid-19 risks.\nGrowth catalysts for share price may include a list of three new product launches next year, which includes the NIO ET7. As the specific timing and pricing for the other two products have not been laid out yet, this will also remain in focus for the upcoming results.\nCurrently, the stock has 26 ‘buy’ recommendations, four ‘holds’ and one ‘sells’. The Bloomberg 12-month consensus target price of $59.00 suggests a potential 16.3% upside from the price at the time of writing.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":2409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846935260,"gmtCreate":1636038831085,"gmtModify":1636039097935,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"very detailed and well thought analysis,superb thanks...like like...","listText":"very detailed and well thought analysis,superb thanks...like like...","text":"very detailed and well thought analysis,superb thanks...like like...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846935260","repostId":"1168874793","repostType":2,"repost":{"id":"1168874793","kind":"news","pubTimestamp":1636035446,"share":"https://www.laohu8.com/m/news/1168874793?lang=zh_CN&edition=full","pubTime":"2021-11-04 22:17","market":"us","language":"en","title":"Ocugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors<blockquote>Ocugen：世卫组织批准科瓦克辛可能会转移投资者的注意力</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168874793","media":"Seeking Alpha","summary":"Summary\n\nOcugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US ","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Ocugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study.</li>  <li>Meanwhile, Bharat has received WHO approval for Emergency Use Listing, meaning the vaccine can be distributed around the world - but that doesn't directly benefit Ocugen.</li>  <li>There are numerous possibilities in play, and Ocugen has no shortage of backers and shorts - the stock is up &gt;4,000% in the past year, but has trodden water for several months.</li>  <li>It's hard to determine what may be in store next for Ocugen shareholders, but if I were one, I'd be holding and hoping. I recap the full story below.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25648bf13e5cb82880f748129c72261c\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Klaus Vedfelt/DigitalVision via Getty Images</span></p><p><blockquote><ul><li>今年早些时候，Ocugen错过了在美国获得科瓦克辛紧急使用授权的机会，但它仍然可以通过一项关键的免疫桥接研究获得批准。</li><li>与此同时，Bharat已获得世卫组织紧急使用清单批准，这意味着该疫苗可以在世界各地分发，但这并没有直接使Ocugen受益。</li><li>存在多种可能性，Ocugen并不缺乏支持者和空头——该股在过去一年中上涨了4,000%以上，但几个月来一直停滞不前。</li><li>很难确定Ocugen股东接下来会发生什么，但如果我是其中之一，我会持有并抱有希望。我在下面回顾了整个故事。</li></ul><p class=\"t-img-caption\"><span>Klaus Vedfelt/DigitalVision来自Getty Images</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Bharat Biotech received an approval from the World Health Organization (\"WHO\") today to join the Emergency Use List (\"EUL\") for vaccines against COVID-19.</p><p><blockquote>巴拉特生物技术公司今天获得世界卫生组织（“世卫组织”）的批准，加入新冠肺炎疫苗的紧急使用清单（“EUL”）。</blockquote></p><p> As most investors will know, Ocugen (OCGN) holds the rights to distribute Covaxin in the US on behalf of Bharat, in exchange for a 45% share of all profits. It also has a similar deal in place for Canada, standing to earn 55% of all profits.</p><p><blockquote>正如大多数投资者所知，Ocugen(OCGN)拥有代表Bharat在美国分销科瓦克辛的权利，以换取所有利润45%的份额。它还为加拿大制定了类似的协议，将赚取所有利润的55%。</blockquote></p><p> Ocugen investors and shorts will be nervously waiting to see how today's news affects the biotech's share price, which initially jumped to $16, but has fallen to $12 post-market.</p><p><blockquote>Ocugen投资者和空头将紧张地等待，看看今天的消息如何影响该生物技术公司的股价，该公司的股价最初跃升至16美元，但盘后已跌至12美元。</blockquote></p><p> In this post I recap the full story, updated from my&nbsp;last post in June, and offer some ways to think about Ocugen's share price in the short and long term.</p><p><blockquote>在这篇文章中，我回顾了整个故事，更新了我6月份的上一篇文章，并提供了一些从短期和长期角度思考Ocugen股价的方法。</blockquote></p><p> <b>Ocugen Stock Jumps From $0.5 To $16 In 3 Months On Bharat COVID Vaccine Deal - The Story So Far</b></p><p><blockquote><b>由于巴拉特新冠疫苗交易，Ocugen股价在3个月内从0.5美元上涨至16美元——迄今为止的故事</b></blockquote></p><p> Ocugen is one of the more bizarre biotech stories of 2021. In mid-December 2020, its shares were trading &lt;$0.5, as the company struggled to develop a preclinical portfolio of gene therapy drug candidates targeting eye disease, having abandoned development of its lead candidate OCU300 in Graft vs Host Disease (\"GvHD\").</p><p><blockquote>Ocugen是2021年更离奇的生物技术故事之一。2020年12月中旬，其股价交易价格&lt;0.5美元，因为该公司放弃了移植物抗宿主病（“GvHD”）主要候选药物OCU300的开发，难以开发针对眼病的基因治疗候选药物的临床前组合。</blockquote></p><p> A delisting from the Nasdaq looked a likely outcome for the company, but then Ocugen's fortunes changed dramatically - the biotech&nbsp;became a partner&nbsp;of Bharat Biotech, developer of the whole-virion inactivated vaccine candidate Covaxin, agreeing to help the Indian Pharma commercialise Covaxin in the US and Canada. Overnight, Ocugen's share price jumped to a price of $3, and by early February, it was trading at $16.</p><p><blockquote>该公司可能会从纳斯达克退市，但随后Ocugen的命运发生了巨大变化——该生物技术公司成为全病毒体灭活疫苗候选物Covaxin开发商Bharat Biotech的合作伙伴，同意帮助这家印度制药公司将Covaxin商业化在美国和加拿大。一夜之间，Ocugen的股价跃升至3美元，到2月初，其交易价格为16美元。</blockquote></p><p> I covered the full story in a&nbsp;note on Ocugen&nbsp;back in June, when Ocugen's shares were trading in a slightly more down-to-earth range of $6 - $10. At that time, the key question was whether Covaxin would receive an Emergency Use Authorization (\"EUA\") from the FDA, allowing it to be marketed and sold in the US.</p><p><blockquote>早在6月份，我就在一篇关于Ocugen的报告中报道了完整的故事，当时Ocugen的股价在6-10美元之间稍微实际一点的范围内交易。当时，关键问题是科瓦克辛是否会获得FDA的紧急使用授权（“EUA”），允许其在美国上市销售。</blockquote></p><p> Unfortunately for Ocugen investors, delays in Bharat's trials of Covaxin in India, where outbreaks of COVID had suddenly become widespread, meant that Ocugen could not get positive Phase 3 trial data in front of the FDA in time for a deadline imposed by the US government - after which it would not accept any further EUA requests for COVID-19 vaccines for the remainder of the pandemic for those companies that have not already begun discussions with the FDA.</p><p><blockquote>对于Ocugen投资者来说不幸的是，Bharat在印度的科瓦克辛病试验被推迟，印度的COVID疫情突然变得广泛，这意味着Ocugen无法在美国政府规定的最后期限前及时向FDA获得积极的3期试验数据——此后，对于那些尚未开始与FDA讨论的公司，它将不会接受任何进一步的EUA请求，为大流行的剩余时间提供COVID-19疫苗。</blockquote></p><p> <b>Ocugen And Bharat Stay The Course - Trials Reveal Strong Efficacy</b></p><p><blockquote><b>Ocugen和Bharat坚持到底——试验显示出强大的功效</b></blockquote></p><p> The bad news about an EUA in the US did not deter Ocugen, Bharat, or Ocugen's investors, however. Despite heavy short interest, as many market watchers concluded Ocugen's share price would be decimated without an EUA for Covaxin in the US, Ocugen management felt that there were other options on the table, including obtaining an EUA in Canada, which falls under its agreement with Bharat, allowing Ocugen to earn 45% of all revenues earned in the region.</p><p><blockquote>然而，有关美国EUA的坏消息并没有阻止Ocugen、Bharat或Ocugen的投资者。尽管空头兴趣浓厚，但许多市场观察人士得出的结论是，如果科瓦克辛在美国没有EUA，Ocugen的股价将大幅下跌，Ocugen管理层认为还有其他选择，包括在加拿大获得EUA，这属于其与Bharat的协议，使Ocugen能够赚取该地区所有收入的45%。</blockquote></p><p> The results of Bharat's ~@5k patient Phase 3 trial in India also came out positive.</p><p><blockquote>Bharat在印度的~@5k患者3期试验结果也是积极的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/862520ed53c876fb96840a3cb9a7a6f9\" tg-width=\"640\" tg-height=\"317\" width=\"100%\" height=\"auto\"><span>Summary of results of Bharat Biotech Phase 3 trial of Covaxin. Source: Ocugen Corporate Presentation.</span></p><p><blockquote><p class=\"t-img-caption\"><span>Bharat Biotech科瓦克辛病3期试验结果总结。资料来源：Ocugen公司介绍。</span></p></blockquote></p><p> As we can see above, Bharat's Covaxin (finally) delivered an efficacy readout of 77.8%, 93.4% efficacy against severe disease - and 65.2% efficacy against the delta variant - the most devastating of all the COVID strains. Furthermore, the National Institute of Allergies and Infectious Diseases advised that a novel vaccine adjuvant developed in Kansas, US with NIAID support, Alhydroxiquim-II, enhanced the overall efficacy of Covaxin.</p><p><blockquote>正如我们在上面看到的，巴拉特的科瓦克辛（最终）提供了77.8%的功效读数，对严重疾病的功效为93.4%，对德尔塔变异毒株的功效为65.2%，这是所有新冠病毒株中最具破坏性的。此外，美国国家过敏和传染病研究所建议，在NIAID的支持下，在美国堪萨斯开发的一种新型疫苗佐剂Alhydroxiquim-II增强了科瓦克辛病的总体疗效。</blockquote></p><p> <b>Bharat Pursues WHO Emergency Use Listing Whilst Ocugen Looks To Canada</b></p><p><blockquote><b>Bharat寻求世界卫生组织紧急使用清单，而Ocugen则将目光投向加拿大</b></blockquote></p><p></p><p> These results, as strong as they are - and it should be noted the efficacy of Pfizer (PFE) and BioNTech's (BNTX) messenger-RNA Comirnaty vaccine against the Delta variant has&nbsp;dropped as low as 39%&nbsp;in studies in Israel - they arrived too late to help Ocugen secure an EUA in the US.</p><p><blockquote>这些结果尽管很强——应该指出的是，辉瑞(PFE)和BioNTech(BNTX)信使RNA Comirnaty疫苗针对德尔塔变异毒株病毒的功效在以色列的研究中已下降至39%——但它们来得太晚了无法帮助Ocugen在美国获得EUA。</blockquote></p><p> Ocugen turned its attention to Canada,announcing&nbsp;a rolling submission to Health Canada on July 15 through its affiliate, Vaccigen, Ltd<b>,</b>allowing for it to submit new data as and when it came in, accelerating the overall review process.</p><p><blockquote>Ocugen将注意力转向加拿大，于7月15日宣布通过其附属公司Vaccigen，Ltd向加拿大卫生部提交滚动申请<b>,</b>允许it部门在收到新数据时提交新数据，从而加快整体审查过程。</blockquote></p><p> If approved, Ocugen will earn 55% of all profits earned from the vaccine, but as I discussed in my&nbsp;last note when providing some discounted cash flow analysis&nbsp;based on optimistic and pessimistic scenarios, it's doubtful if the Canadian government's purchases alone would provide a significant boot to Ocugen's current market cap valuation of $2.5bn, or its share price of $12.7.</p><p><blockquote>如果获得批准，Ocugen将获得该疫苗所有利润的55%，但正如我在上一篇笔记中讨论的那样，在提供一些基于乐观和悲观情景的贴现现金流分析时，仅加拿大政府的购买是否会提供这一结果值得怀疑。Ocugen目前的市值估值为25亿美元，股价为12.7美元。</blockquote></p><p> The US is the key for Ocugen, and management has by no means given up on this opportunity. In late October, Ocugen made an Investigational New Drug (\"IND\")&nbsp;submission&nbsp;to the FDA. Ocugen's plan is to initiate a Phase 3 \"immuno-bridging study,\" enrolling several hundred healthy adults in the U.S, who will receive 2 doses of Covaxin or placebo, 28 days apart. The endpoints are described by management (in an October 27th press release) as follows:</p><p><blockquote>美国是Ocugen的关键，管理层绝不会放弃这个机会。10月下旬，Ocugen向FDA提交了研究性新药（“IND”）。Ocugen的计划是启动一项3期“免疫桥接研究”，在美国招募数百名健康成年人，他们将接受2剂科瓦克辛或安慰剂，间隔28天。管理层（在10月27日的新闻稿中）对这些终点的描述如下：</blockquote></p><p>   The primary endpoint will compare blood-based samples taken from U.S. participants who received COVAXIN™ with samples of the participants in the Phase 3 efficacy trial conducted in India. The secondary endpoint involves testing the vaccine's immunogenic profile. The study will also evaluate safety and tolerability in the U.S. population.  Ocugen hopes to have the study complete before the end of H122, if it is approved by the FDA, which has yet to make a decision. If the FDA does give the green light, then the US market - and Ocugen's 45% of all profits - is suddenly back on the table.</p><p><blockquote>主要终点将比较从接受科瓦克辛的美国参与者身上采集的血液样本™在印度进行的3期疗效试验的参与者样本。次要终点包括测试疫苗的免疫原性特征。该研究还将评估美国人群的安全性和耐受性。如果FDA批准，Ocugen希望在H122结束前完成这项研究，但FDA尚未做出决定。如果FDA真的开了绿灯，那么美国市场——以及Ocugen 45%的利润——就会突然回到桌面上。</blockquote></p><p> Meanwhile, Bharat Biotech&nbsp;received notification&nbsp;today that the World Health Organization has approved its application for an Emergency Use Listing (\"EUL\"), meaning Covaxin will now likely be accepted by a host of foreign governments, and that Indians who have received the vaccine will have fewer problems traveling overseas.</p><p><blockquote>与此同时，Bharat Biotech今天收到通知，世界卫生组织已批准其紧急使用清单（“EUL”）的申请，这意味着科瓦克辛现在可能会被许多外国政府接受，接种疫苗的印度人出国旅行的问题将更少。</blockquote></p><p> It's great news for Bharat, who join the likes of Pfizer / BioNTech, Johnson &amp; Johnson (JNJ), SinoPharm, Moderna (MRNA) and AstraZeneca (AZN) on the list of EUL-approved vaccine developers - but it is not necessarily great news for Ocugen.</p><p><blockquote>这对Bharat来说是个好消息，他与辉瑞/BioNTech、强生(JNJ)、国药控股、Moderna(MRNA)和阿斯利康(AZN)等公司一起加入了EUL批准的疫苗开发商名单，但这不一定是好消息对于Ocugen来说。</blockquote></p><p> Vaccines on the EUL list are permitted to be sent to government's around the world as part of the&nbsp;COVAX scheme, designed to create equitable vaccine distribution around the world, including poorer countries, but the US is a donor to this scheme, not a beneficiary, meaning that Ocugen effectively gets no benefit, and no revenues, as a result of the WHO approval for Covaxin.</p><p><blockquote>作为COVAX计划的一部分，EUL清单上的疫苗被允许发送到世界各地的政府，该计划旨在在世界各地（包括较贫穷国家）实现公平的疫苗分配，但美国是该计划的捐助者，而不是受益者，这意味着由于世卫组织批准科瓦克辛，Ocugen实际上没有获得任何好处，也没有收入。</blockquote></p><p> <b>Ocugen Stock Is Already On A Downtrend - All Eyes Will Now Be On Health Canada And The FDA</b></p><p><blockquote><b>Ocugen股票已经处于下降趋势——现在所有人的目光都集中在加拿大卫生部和FDA身上</b></blockquote></p><p> Ocugen stock bounced from a price of ~$9, to a peak of ~$16 in trading today, however the share price quickly began to decline, and finished at a price of $12.7. Post-market, shares were down another 10%.</p><p><blockquote>Ocugen股票在今天的交易中从约9美元的价格反弹至约16美元的峰值，但股价很快开始下跌，最终收于12.7美元。盘后，股价又下跌10%。</blockquote></p><p> That reflects the fact that the WHO approval for Covaxin does little to improve Ocugen's own fortunes, and in all honesty, was something of a red herring.</p><p><blockquote>这反映出这样一个事实：世卫组织对科瓦克辛的批准对改善Ocugen自身的命运几乎没有什么作用，而且说实话，这有点转移视线。</blockquote></p><p> Ocugen investors, and Ocugen shorts, are desperate to know what the future holds for Covaxin in the US and Canada, but they will have to wait until Health Canada and the FDA rule respectively on an Emergency Use Authorization, and an approval to begin a drastically reduced pivotal trial in the US.</p><p><blockquote>Ocugen投资者和Ocugen空头迫切想知道科瓦克辛在美国和加拿大的未来会怎样，但他们必须等到加拿大卫生部和FDA分别就紧急使用授权做出裁决，并批准开始在美国进行大幅减少的关键试验。</blockquote></p><p> Ironically, despite all of the news flow and the publication of Covaxin Phase 3 trial data, and the EUA granted to Covaxin by the Indian government, Ocugen's fortunes are in a similar place to where they were when I last covered the company - barring the US EUA opportunity.</p><p><blockquote>具有讽刺意味的是，尽管有所有的新闻报道和科瓦克辛3期试验数据的公布，以及印度政府授予科瓦克辛的EUA，但Ocugen的命运与我上次报道该公司时相似——除了美国EUA的机会。</blockquote></p><p> That opportunity - the one that may have sent Ocugen shares through the roof - has gone, but as I argued in my last post, I think it's possible that the US would not object to stockpiling some of the Covaxin shot, which has a differentiated mechanism of action, and a shelf life of up to years if stored at 2- 8 degrees centigrade.</p><p><blockquote>这个机会——可能让Ocugen股价飙升的机会——已经过去了，但正如我在上一篇文章中所说，我认为美国可能不会反对储存一些科瓦克辛疫苗，它具有差异化的作用机制，如果储存在2-8摄氏度下，保质期可达数年。</blockquote></p><p> Covaxin may have benefits that other vaccines do not, the reasoning may go, such as its ability to induce a Th1 response, conferring cell-mediated immunity and offering durable protection, and enhanced protection against COVID variants, which is the primary concern at the present time.</p><p><blockquote>理由可能是，科瓦克辛可能具有其他疫苗没有的好处，例如它能够诱导Th1反应，赋予细胞介导的免疫并提供持久的保护，以及增强对COVID变异的保护，这是目前主要关注的问题。</blockquote></p><p> On the other hand, the US may now be able to obtain supply directly from Bharat via the WHO and be in a position to cut Ocugen - the middleman - out of any deal.</p><p><blockquote>另一方面，美国现在可能能够通过世卫组织直接从巴拉特获得供应，并能够将中间人Ocugen排除在任何交易之外。</blockquote></p><p></p><p> The fact of the matter is that Ocugen's opportunity with Bharat and Covaxin has always appeared to be one that required expediency of execution, in order to capitalize on a US market opportunity that's uncertain, perhaps negligible, at worst, and a potential multi-billion opportunity at best.</p><p><blockquote>事实是，Ocugen与巴拉特和科瓦克辛的机会似乎总是需要权宜之计的执行，以便利用美国市场的机会，这种机会在最坏的情况下是不确定的，也许可以忽略不计，在最好的情况下是潜在的数十亿美元的机会。</blockquote></p><p> Nobody knows even if Ocugen will get an opportunity to market Covaxin in the US, but if it does, it will need to negotiate a tricky Phase 3 trial first, which could take us into the latter half of next year. Equally, no-one yet knows if Health Canada will approve the vaccine.</p><p><blockquote>没有人知道Ocugen是否有机会在美国销售科瓦克辛，但如果有机会，它将需要首先谈判一项棘手的3期试验，这可能会让我们进入明年下半年。同样，目前还没有人知道加拿大卫生部是否会批准该疫苗。</blockquote></p><p> <b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p> To summarise the current state of affairs, I would lean toward an approval in Canada - if Covaxin is good enough for the WHO, why would it not be good enough for Canada?</p><p><blockquote>总结一下目前的情况，我倾向于加拿大的批准——如果科瓦克辛对世卫组织来说足够好，为什么对加拿大来说不够好呢？</blockquote></p><p> But how much product will Canada buy? Probably enough to create a substantial price spike for Ocugen stock, although demand is unlikely to be high enough to sustain that spike long term.</p><p><blockquote>但是加拿大会购买多少产品呢？这可能足以导致Ocugen股票的价格大幅飙升，尽管需求不太可能高到足以长期维持这种飙升。</blockquote></p><p> How much would the US buy if Covaxin was approved in the US? Again, I cannot see it being a high enough volume to catapult Ocugen's market cap above say $10bn, but if it buys any at all, Ocugen's market valuation is more or less guaranteed to surge, at least temporarily.</p><p><blockquote>如果科瓦克辛在美国获得批准，美国会买多少？再说一次，我认为这个交易量不足以将Ocugen的市值推高到100亿美元以上，但如果它真的购买任何股票，Ocugen的市值或多或少肯定会飙升，至少是暂时的。</blockquote></p><p> In conclusion, I would argue that there is enough intrigue and opportunity in the Ocugen story to keep investors interested - on both the short and long sides. The WHO approval does not directly benefit Ocugen revenues wise, but it's another win for Covaxin, which is in turn a win for Ocugen.</p><p><blockquote>总之，我认为Ocugen的故事中有足够的阴谋和机会让投资者保持兴趣——无论是空头还是多头。世界卫生组织的批准并没有直接有利于Ocugen的收入，但这是科瓦克辛的又一次胜利，这反过来也是Ocugen的胜利。</blockquote></p><p> If I has been holding Ocugen stock since December last year, when it traded at &gt;$0.5, frankly I would have sold by now, but if I had opened a position at ~$10, in expectation of doubling my money on a US approval, I would still be (nervously) holding.</p><p><blockquote>如果我自去年12月以来一直持有Ocugen股票，当时其交易价格&gt;0.5美元，坦率地说，我现在就会卖出，但如果我以约10美元的价格建仓，期望在美国批准后我的资金翻倍，我仍然会（紧张地）持有。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors<blockquote>Ocugen：世卫组织批准科瓦克辛可能会转移投资者的注意力</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors<blockquote>Ocugen：世卫组织批准科瓦克辛可能会转移投资者的注意力</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-11-04 22:17</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Ocugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study.</li>  <li>Meanwhile, Bharat has received WHO approval for Emergency Use Listing, meaning the vaccine can be distributed around the world - but that doesn't directly benefit Ocugen.</li>  <li>There are numerous possibilities in play, and Ocugen has no shortage of backers and shorts - the stock is up &gt;4,000% in the past year, but has trodden water for several months.</li>  <li>It's hard to determine what may be in store next for Ocugen shareholders, but if I were one, I'd be holding and hoping. I recap the full story below.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25648bf13e5cb82880f748129c72261c\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Klaus Vedfelt/DigitalVision via Getty Images</span></p><p><blockquote><ul><li>今年早些时候，Ocugen错过了在美国获得科瓦克辛紧急使用授权的机会，但它仍然可以通过一项关键的免疫桥接研究获得批准。</li><li>与此同时，Bharat已获得世卫组织紧急使用清单批准，这意味着该疫苗可以在世界各地分发，但这并没有直接使Ocugen受益。</li><li>存在多种可能性，Ocugen并不缺乏支持者和空头——该股在过去一年中上涨了4,000%以上，但几个月来一直停滞不前。</li><li>很难确定Ocugen股东接下来会发生什么，但如果我是其中之一，我会持有并抱有希望。我在下面回顾了整个故事。</li></ul><p class=\"t-img-caption\"><span>Klaus Vedfelt/DigitalVision来自Getty Images</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Bharat Biotech received an approval from the World Health Organization (\"WHO\") today to join the Emergency Use List (\"EUL\") for vaccines against COVID-19.</p><p><blockquote>巴拉特生物技术公司今天获得世界卫生组织（“世卫组织”）的批准，加入新冠肺炎疫苗的紧急使用清单（“EUL”）。</blockquote></p><p> As most investors will know, Ocugen (OCGN) holds the rights to distribute Covaxin in the US on behalf of Bharat, in exchange for a 45% share of all profits. It also has a similar deal in place for Canada, standing to earn 55% of all profits.</p><p><blockquote>正如大多数投资者所知，Ocugen(OCGN)拥有代表Bharat在美国分销科瓦克辛的权利，以换取所有利润45%的份额。它还为加拿大制定了类似的协议，将赚取所有利润的55%。</blockquote></p><p> Ocugen investors and shorts will be nervously waiting to see how today's news affects the biotech's share price, which initially jumped to $16, but has fallen to $12 post-market.</p><p><blockquote>Ocugen投资者和空头将紧张地等待，看看今天的消息如何影响该生物技术公司的股价，该公司的股价最初跃升至16美元，但盘后已跌至12美元。</blockquote></p><p> In this post I recap the full story, updated from my&nbsp;last post in June, and offer some ways to think about Ocugen's share price in the short and long term.</p><p><blockquote>在这篇文章中，我回顾了整个故事，更新了我6月份的上一篇文章，并提供了一些从短期和长期角度思考Ocugen股价的方法。</blockquote></p><p> <b>Ocugen Stock Jumps From $0.5 To $16 In 3 Months On Bharat COVID Vaccine Deal - The Story So Far</b></p><p><blockquote><b>由于巴拉特新冠疫苗交易，Ocugen股价在3个月内从0.5美元上涨至16美元——迄今为止的故事</b></blockquote></p><p> Ocugen is one of the more bizarre biotech stories of 2021. In mid-December 2020, its shares were trading &lt;$0.5, as the company struggled to develop a preclinical portfolio of gene therapy drug candidates targeting eye disease, having abandoned development of its lead candidate OCU300 in Graft vs Host Disease (\"GvHD\").</p><p><blockquote>Ocugen是2021年更离奇的生物技术故事之一。2020年12月中旬，其股价交易价格&lt;0.5美元，因为该公司放弃了移植物抗宿主病（“GvHD”）主要候选药物OCU300的开发，难以开发针对眼病的基因治疗候选药物的临床前组合。</blockquote></p><p> A delisting from the Nasdaq looked a likely outcome for the company, but then Ocugen's fortunes changed dramatically - the biotech&nbsp;became a partner&nbsp;of Bharat Biotech, developer of the whole-virion inactivated vaccine candidate Covaxin, agreeing to help the Indian Pharma commercialise Covaxin in the US and Canada. Overnight, Ocugen's share price jumped to a price of $3, and by early February, it was trading at $16.</p><p><blockquote>该公司可能会从纳斯达克退市，但随后Ocugen的命运发生了巨大变化——该生物技术公司成为全病毒体灭活疫苗候选物Covaxin开发商Bharat Biotech的合作伙伴，同意帮助这家印度制药公司将Covaxin商业化在美国和加拿大。一夜之间，Ocugen的股价跃升至3美元，到2月初，其交易价格为16美元。</blockquote></p><p> I covered the full story in a&nbsp;note on Ocugen&nbsp;back in June, when Ocugen's shares were trading in a slightly more down-to-earth range of $6 - $10. At that time, the key question was whether Covaxin would receive an Emergency Use Authorization (\"EUA\") from the FDA, allowing it to be marketed and sold in the US.</p><p><blockquote>早在6月份，我就在一篇关于Ocugen的报告中报道了完整的故事，当时Ocugen的股价在6-10美元之间稍微实际一点的范围内交易。当时，关键问题是科瓦克辛是否会获得FDA的紧急使用授权（“EUA”），允许其在美国上市销售。</blockquote></p><p> Unfortunately for Ocugen investors, delays in Bharat's trials of Covaxin in India, where outbreaks of COVID had suddenly become widespread, meant that Ocugen could not get positive Phase 3 trial data in front of the FDA in time for a deadline imposed by the US government - after which it would not accept any further EUA requests for COVID-19 vaccines for the remainder of the pandemic for those companies that have not already begun discussions with the FDA.</p><p><blockquote>对于Ocugen投资者来说不幸的是，Bharat在印度的科瓦克辛病试验被推迟，印度的COVID疫情突然变得广泛，这意味着Ocugen无法在美国政府规定的最后期限前及时向FDA获得积极的3期试验数据——此后，对于那些尚未开始与FDA讨论的公司，它将不会接受任何进一步的EUA请求，为大流行的剩余时间提供COVID-19疫苗。</blockquote></p><p> <b>Ocugen And Bharat Stay The Course - Trials Reveal Strong Efficacy</b></p><p><blockquote><b>Ocugen和Bharat坚持到底——试验显示出强大的功效</b></blockquote></p><p> The bad news about an EUA in the US did not deter Ocugen, Bharat, or Ocugen's investors, however. Despite heavy short interest, as many market watchers concluded Ocugen's share price would be decimated without an EUA for Covaxin in the US, Ocugen management felt that there were other options on the table, including obtaining an EUA in Canada, which falls under its agreement with Bharat, allowing Ocugen to earn 45% of all revenues earned in the region.</p><p><blockquote>然而，有关美国EUA的坏消息并没有阻止Ocugen、Bharat或Ocugen的投资者。尽管空头兴趣浓厚，但许多市场观察人士得出的结论是，如果科瓦克辛在美国没有EUA，Ocugen的股价将大幅下跌，Ocugen管理层认为还有其他选择，包括在加拿大获得EUA，这属于其与Bharat的协议，使Ocugen能够赚取该地区所有收入的45%。</blockquote></p><p> The results of Bharat's ~@5k patient Phase 3 trial in India also came out positive.</p><p><blockquote>Bharat在印度的~@5k患者3期试验结果也是积极的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/862520ed53c876fb96840a3cb9a7a6f9\" tg-width=\"640\" tg-height=\"317\" width=\"100%\" height=\"auto\"><span>Summary of results of Bharat Biotech Phase 3 trial of Covaxin. Source: Ocugen Corporate Presentation.</span></p><p><blockquote><p class=\"t-img-caption\"><span>Bharat Biotech科瓦克辛病3期试验结果总结。资料来源：Ocugen公司介绍。</span></p></blockquote></p><p> As we can see above, Bharat's Covaxin (finally) delivered an efficacy readout of 77.8%, 93.4% efficacy against severe disease - and 65.2% efficacy against the delta variant - the most devastating of all the COVID strains. Furthermore, the National Institute of Allergies and Infectious Diseases advised that a novel vaccine adjuvant developed in Kansas, US with NIAID support, Alhydroxiquim-II, enhanced the overall efficacy of Covaxin.</p><p><blockquote>正如我们在上面看到的，巴拉特的科瓦克辛（最终）提供了77.8%的功效读数，对严重疾病的功效为93.4%，对德尔塔变异毒株的功效为65.2%，这是所有新冠病毒株中最具破坏性的。此外，美国国家过敏和传染病研究所建议，在NIAID的支持下，在美国堪萨斯开发的一种新型疫苗佐剂Alhydroxiquim-II增强了科瓦克辛病的总体疗效。</blockquote></p><p> <b>Bharat Pursues WHO Emergency Use Listing Whilst Ocugen Looks To Canada</b></p><p><blockquote><b>Bharat寻求世界卫生组织紧急使用清单，而Ocugen则将目光投向加拿大</b></blockquote></p><p></p><p> These results, as strong as they are - and it should be noted the efficacy of Pfizer (PFE) and BioNTech's (BNTX) messenger-RNA Comirnaty vaccine against the Delta variant has&nbsp;dropped as low as 39%&nbsp;in studies in Israel - they arrived too late to help Ocugen secure an EUA in the US.</p><p><blockquote>这些结果尽管很强——应该指出的是，辉瑞(PFE)和BioNTech(BNTX)信使RNA Comirnaty疫苗针对德尔塔变异毒株病毒的功效在以色列的研究中已下降至39%——但它们来得太晚了无法帮助Ocugen在美国获得EUA。</blockquote></p><p> Ocugen turned its attention to Canada,announcing&nbsp;a rolling submission to Health Canada on July 15 through its affiliate, Vaccigen, Ltd<b>,</b>allowing for it to submit new data as and when it came in, accelerating the overall review process.</p><p><blockquote>Ocugen将注意力转向加拿大，于7月15日宣布通过其附属公司Vaccigen，Ltd向加拿大卫生部提交滚动申请<b>,</b>允许it部门在收到新数据时提交新数据，从而加快整体审查过程。</blockquote></p><p> If approved, Ocugen will earn 55% of all profits earned from the vaccine, but as I discussed in my&nbsp;last note when providing some discounted cash flow analysis&nbsp;based on optimistic and pessimistic scenarios, it's doubtful if the Canadian government's purchases alone would provide a significant boot to Ocugen's current market cap valuation of $2.5bn, or its share price of $12.7.</p><p><blockquote>如果获得批准，Ocugen将获得该疫苗所有利润的55%，但正如我在上一篇笔记中讨论的那样，在提供一些基于乐观和悲观情景的贴现现金流分析时，仅加拿大政府的购买是否会提供这一结果值得怀疑。Ocugen目前的市值估值为25亿美元，股价为12.7美元。</blockquote></p><p> The US is the key for Ocugen, and management has by no means given up on this opportunity. In late October, Ocugen made an Investigational New Drug (\"IND\")&nbsp;submission&nbsp;to the FDA. Ocugen's plan is to initiate a Phase 3 \"immuno-bridging study,\" enrolling several hundred healthy adults in the U.S, who will receive 2 doses of Covaxin or placebo, 28 days apart. The endpoints are described by management (in an October 27th press release) as follows:</p><p><blockquote>美国是Ocugen的关键，管理层绝不会放弃这个机会。10月下旬，Ocugen向FDA提交了研究性新药（“IND”）。Ocugen的计划是启动一项3期“免疫桥接研究”，在美国招募数百名健康成年人，他们将接受2剂科瓦克辛或安慰剂，间隔28天。管理层（在10月27日的新闻稿中）对这些终点的描述如下：</blockquote></p><p>   The primary endpoint will compare blood-based samples taken from U.S. participants who received COVAXIN™ with samples of the participants in the Phase 3 efficacy trial conducted in India. The secondary endpoint involves testing the vaccine's immunogenic profile. The study will also evaluate safety and tolerability in the U.S. population.  Ocugen hopes to have the study complete before the end of H122, if it is approved by the FDA, which has yet to make a decision. If the FDA does give the green light, then the US market - and Ocugen's 45% of all profits - is suddenly back on the table.</p><p><blockquote>主要终点将比较从接受科瓦克辛的美国参与者身上采集的血液样本™在印度进行的3期疗效试验的参与者样本。次要终点包括测试疫苗的免疫原性特征。该研究还将评估美国人群的安全性和耐受性。如果FDA批准，Ocugen希望在H122结束前完成这项研究，但FDA尚未做出决定。如果FDA真的开了绿灯，那么美国市场——以及Ocugen 45%的利润——就会突然回到桌面上。</blockquote></p><p> Meanwhile, Bharat Biotech&nbsp;received notification&nbsp;today that the World Health Organization has approved its application for an Emergency Use Listing (\"EUL\"), meaning Covaxin will now likely be accepted by a host of foreign governments, and that Indians who have received the vaccine will have fewer problems traveling overseas.</p><p><blockquote>与此同时，Bharat Biotech今天收到通知，世界卫生组织已批准其紧急使用清单（“EUL”）的申请，这意味着科瓦克辛现在可能会被许多外国政府接受，接种疫苗的印度人出国旅行的问题将更少。</blockquote></p><p> It's great news for Bharat, who join the likes of Pfizer / BioNTech, Johnson &amp; Johnson (JNJ), SinoPharm, Moderna (MRNA) and AstraZeneca (AZN) on the list of EUL-approved vaccine developers - but it is not necessarily great news for Ocugen.</p><p><blockquote>这对Bharat来说是个好消息，他与辉瑞/BioNTech、强生(JNJ)、国药控股、Moderna(MRNA)和阿斯利康(AZN)等公司一起加入了EUL批准的疫苗开发商名单，但这不一定是好消息对于Ocugen来说。</blockquote></p><p> Vaccines on the EUL list are permitted to be sent to government's around the world as part of the&nbsp;COVAX scheme, designed to create equitable vaccine distribution around the world, including poorer countries, but the US is a donor to this scheme, not a beneficiary, meaning that Ocugen effectively gets no benefit, and no revenues, as a result of the WHO approval for Covaxin.</p><p><blockquote>作为COVAX计划的一部分，EUL清单上的疫苗被允许发送到世界各地的政府，该计划旨在在世界各地（包括较贫穷国家）实现公平的疫苗分配，但美国是该计划的捐助者，而不是受益者，这意味着由于世卫组织批准科瓦克辛，Ocugen实际上没有获得任何好处，也没有收入。</blockquote></p><p> <b>Ocugen Stock Is Already On A Downtrend - All Eyes Will Now Be On Health Canada And The FDA</b></p><p><blockquote><b>Ocugen股票已经处于下降趋势——现在所有人的目光都集中在加拿大卫生部和FDA身上</b></blockquote></p><p> Ocugen stock bounced from a price of ~$9, to a peak of ~$16 in trading today, however the share price quickly began to decline, and finished at a price of $12.7. Post-market, shares were down another 10%.</p><p><blockquote>Ocugen股票在今天的交易中从约9美元的价格反弹至约16美元的峰值，但股价很快开始下跌，最终收于12.7美元。盘后，股价又下跌10%。</blockquote></p><p> That reflects the fact that the WHO approval for Covaxin does little to improve Ocugen's own fortunes, and in all honesty, was something of a red herring.</p><p><blockquote>这反映出这样一个事实：世卫组织对科瓦克辛的批准对改善Ocugen自身的命运几乎没有什么作用，而且说实话，这有点转移视线。</blockquote></p><p> Ocugen investors, and Ocugen shorts, are desperate to know what the future holds for Covaxin in the US and Canada, but they will have to wait until Health Canada and the FDA rule respectively on an Emergency Use Authorization, and an approval to begin a drastically reduced pivotal trial in the US.</p><p><blockquote>Ocugen投资者和Ocugen空头迫切想知道科瓦克辛在美国和加拿大的未来会怎样，但他们必须等到加拿大卫生部和FDA分别就紧急使用授权做出裁决，并批准开始在美国进行大幅减少的关键试验。</blockquote></p><p> Ironically, despite all of the news flow and the publication of Covaxin Phase 3 trial data, and the EUA granted to Covaxin by the Indian government, Ocugen's fortunes are in a similar place to where they were when I last covered the company - barring the US EUA opportunity.</p><p><blockquote>具有讽刺意味的是，尽管有所有的新闻报道和科瓦克辛3期试验数据的公布，以及印度政府授予科瓦克辛的EUA，但Ocugen的命运与我上次报道该公司时相似——除了美国EUA的机会。</blockquote></p><p> That opportunity - the one that may have sent Ocugen shares through the roof - has gone, but as I argued in my last post, I think it's possible that the US would not object to stockpiling some of the Covaxin shot, which has a differentiated mechanism of action, and a shelf life of up to years if stored at 2- 8 degrees centigrade.</p><p><blockquote>这个机会——可能让Ocugen股价飙升的机会——已经过去了，但正如我在上一篇文章中所说，我认为美国可能不会反对储存一些科瓦克辛疫苗，它具有差异化的作用机制，如果储存在2-8摄氏度下，保质期可达数年。</blockquote></p><p> Covaxin may have benefits that other vaccines do not, the reasoning may go, such as its ability to induce a Th1 response, conferring cell-mediated immunity and offering durable protection, and enhanced protection against COVID variants, which is the primary concern at the present time.</p><p><blockquote>理由可能是，科瓦克辛可能具有其他疫苗没有的好处，例如它能够诱导Th1反应，赋予细胞介导的免疫并提供持久的保护，以及增强对COVID变异的保护，这是目前主要关注的问题。</blockquote></p><p> On the other hand, the US may now be able to obtain supply directly from Bharat via the WHO and be in a position to cut Ocugen - the middleman - out of any deal.</p><p><blockquote>另一方面，美国现在可能能够通过世卫组织直接从巴拉特获得供应，并能够将中间人Ocugen排除在任何交易之外。</blockquote></p><p></p><p> The fact of the matter is that Ocugen's opportunity with Bharat and Covaxin has always appeared to be one that required expediency of execution, in order to capitalize on a US market opportunity that's uncertain, perhaps negligible, at worst, and a potential multi-billion opportunity at best.</p><p><blockquote>事实是，Ocugen与巴拉特和科瓦克辛的机会似乎总是需要权宜之计的执行，以便利用美国市场的机会，这种机会在最坏的情况下是不确定的，也许可以忽略不计，在最好的情况下是潜在的数十亿美元的机会。</blockquote></p><p> Nobody knows even if Ocugen will get an opportunity to market Covaxin in the US, but if it does, it will need to negotiate a tricky Phase 3 trial first, which could take us into the latter half of next year. Equally, no-one yet knows if Health Canada will approve the vaccine.</p><p><blockquote>没有人知道Ocugen是否有机会在美国销售科瓦克辛，但如果有机会，它将需要首先谈判一项棘手的3期试验，这可能会让我们进入明年下半年。同样，目前还没有人知道加拿大卫生部是否会批准该疫苗。</blockquote></p><p> <b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p> To summarise the current state of affairs, I would lean toward an approval in Canada - if Covaxin is good enough for the WHO, why would it not be good enough for Canada?</p><p><blockquote>总结一下目前的情况，我倾向于加拿大的批准——如果科瓦克辛对世卫组织来说足够好，为什么对加拿大来说不够好呢？</blockquote></p><p> But how much product will Canada buy? Probably enough to create a substantial price spike for Ocugen stock, although demand is unlikely to be high enough to sustain that spike long term.</p><p><blockquote>但是加拿大会购买多少产品呢？这可能足以导致Ocugen股票的价格大幅飙升，尽管需求不太可能高到足以长期维持这种飙升。</blockquote></p><p> How much would the US buy if Covaxin was approved in the US? Again, I cannot see it being a high enough volume to catapult Ocugen's market cap above say $10bn, but if it buys any at all, Ocugen's market valuation is more or less guaranteed to surge, at least temporarily.</p><p><blockquote>如果科瓦克辛在美国获得批准，美国会买多少？再说一次，我认为这个交易量不足以将Ocugen的市值推高到100亿美元以上，但如果它真的购买任何股票，Ocugen的市值或多或少肯定会飙升，至少是暂时的。</blockquote></p><p> In conclusion, I would argue that there is enough intrigue and opportunity in the Ocugen story to keep investors interested - on both the short and long sides. The WHO approval does not directly benefit Ocugen revenues wise, but it's another win for Covaxin, which is in turn a win for Ocugen.</p><p><blockquote>总之，我认为Ocugen的故事中有足够的阴谋和机会让投资者保持兴趣——无论是空头还是多头。世界卫生组织的批准并没有直接有利于Ocugen的收入，但这是科瓦克辛的又一次胜利，这反过来也是Ocugen的胜利。</blockquote></p><p> If I has been holding Ocugen stock since December last year, when it traded at &gt;$0.5, frankly I would have sold by now, but if I had opened a position at ~$10, in expectation of doubling my money on a US approval, I would still be (nervously) holding.</p><p><blockquote>如果我自去年12月以来一直持有Ocugen股票，当时其交易价格&gt;0.5美元，坦率地说，我现在就会卖出，但如果我以约10美元的价格建仓，期望在美国批准后我的资金翻倍，我仍然会（紧张地）持有。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4465154-ocugen-approval-for-covaxin-red-herring-for-investors\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/article/4465154-ocugen-approval-for-covaxin-red-herring-for-investors","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168874793","content_text":"Summary\n\nOcugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study.\nMeanwhile, Bharat has received WHO approval for Emergency Use Listing, meaning the vaccine can be distributed around the world - but that doesn't directly benefit Ocugen.\nThere are numerous possibilities in play, and Ocugen has no shortage of backers and shorts - the stock is up >4,000% in the past year, but has trodden water for several months.\nIt's hard to determine what may be in store next for Ocugen shareholders, but if I were one, I'd be holding and hoping. I recap the full story below.\n\nKlaus Vedfelt/DigitalVision via Getty Images\nInvestment Thesis\nBharat Biotech received an approval from the World Health Organization (\"WHO\") today to join the Emergency Use List (\"EUL\") for vaccines against COVID-19.\nAs most investors will know, Ocugen (OCGN) holds the rights to distribute Covaxin in the US on behalf of Bharat, in exchange for a 45% share of all profits. It also has a similar deal in place for Canada, standing to earn 55% of all profits.\nOcugen investors and shorts will be nervously waiting to see how today's news affects the biotech's share price, which initially jumped to $16, but has fallen to $12 post-market.\nIn this post I recap the full story, updated from my last post in June, and offer some ways to think about Ocugen's share price in the short and long term.\nOcugen Stock Jumps From $0.5 To $16 In 3 Months On Bharat COVID Vaccine Deal - The Story So Far\nOcugen is one of the more bizarre biotech stories of 2021. In mid-December 2020, its shares were trading <$0.5, as the company struggled to develop a preclinical portfolio of gene therapy drug candidates targeting eye disease, having abandoned development of its lead candidate OCU300 in Graft vs Host Disease (\"GvHD\").\nA delisting from the Nasdaq looked a likely outcome for the company, but then Ocugen's fortunes changed dramatically - the biotech became a partner of Bharat Biotech, developer of the whole-virion inactivated vaccine candidate Covaxin, agreeing to help the Indian Pharma commercialise Covaxin in the US and Canada. Overnight, Ocugen's share price jumped to a price of $3, and by early February, it was trading at $16.\nI covered the full story in a note on Ocugen back in June, when Ocugen's shares were trading in a slightly more down-to-earth range of $6 - $10. At that time, the key question was whether Covaxin would receive an Emergency Use Authorization (\"EUA\") from the FDA, allowing it to be marketed and sold in the US.\nUnfortunately for Ocugen investors, delays in Bharat's trials of Covaxin in India, where outbreaks of COVID had suddenly become widespread, meant that Ocugen could not get positive Phase 3 trial data in front of the FDA in time for a deadline imposed by the US government - after which it would not accept any further EUA requests for COVID-19 vaccines for the remainder of the pandemic for those companies that have not already begun discussions with the FDA.\nOcugen And Bharat Stay The Course - Trials Reveal Strong Efficacy\nThe bad news about an EUA in the US did not deter Ocugen, Bharat, or Ocugen's investors, however. Despite heavy short interest, as many market watchers concluded Ocugen's share price would be decimated without an EUA for Covaxin in the US, Ocugen management felt that there were other options on the table, including obtaining an EUA in Canada, which falls under its agreement with Bharat, allowing Ocugen to earn 45% of all revenues earned in the region.\nThe results of Bharat's ~@5k patient Phase 3 trial in India also came out positive.\nSummary of results of Bharat Biotech Phase 3 trial of Covaxin. Source: Ocugen Corporate Presentation.\nAs we can see above, Bharat's Covaxin (finally) delivered an efficacy readout of 77.8%, 93.4% efficacy against severe disease - and 65.2% efficacy against the delta variant - the most devastating of all the COVID strains. Furthermore, the National Institute of Allergies and Infectious Diseases advised that a novel vaccine adjuvant developed in Kansas, US with NIAID support, Alhydroxiquim-II, enhanced the overall efficacy of Covaxin.\nBharat Pursues WHO Emergency Use Listing Whilst Ocugen Looks To Canada\nThese results, as strong as they are - and it should be noted the efficacy of Pfizer (PFE) and BioNTech's (BNTX) messenger-RNA Comirnaty vaccine against the Delta variant has dropped as low as 39% in studies in Israel - they arrived too late to help Ocugen secure an EUA in the US.\nOcugen turned its attention to Canada,announcing a rolling submission to Health Canada on July 15 through its affiliate, Vaccigen, Ltd,allowing for it to submit new data as and when it came in, accelerating the overall review process.\nIf approved, Ocugen will earn 55% of all profits earned from the vaccine, but as I discussed in my last note when providing some discounted cash flow analysis based on optimistic and pessimistic scenarios, it's doubtful if the Canadian government's purchases alone would provide a significant boot to Ocugen's current market cap valuation of $2.5bn, or its share price of $12.7.\nThe US is the key for Ocugen, and management has by no means given up on this opportunity. In late October, Ocugen made an Investigational New Drug (\"IND\") submission to the FDA. Ocugen's plan is to initiate a Phase 3 \"immuno-bridging study,\" enrolling several hundred healthy adults in the U.S, who will receive 2 doses of Covaxin or placebo, 28 days apart. The endpoints are described by management (in an October 27th press release) as follows:\n\n The primary endpoint will compare blood-based samples taken from U.S. participants who received COVAXIN™ with samples of the participants in the Phase 3 efficacy trial conducted in India. The secondary endpoint involves testing the vaccine's immunogenic profile. The study will also evaluate safety and tolerability in the U.S. population.\n\nOcugen hopes to have the study complete before the end of H122, if it is approved by the FDA, which has yet to make a decision. If the FDA does give the green light, then the US market - and Ocugen's 45% of all profits - is suddenly back on the table.\nMeanwhile, Bharat Biotech received notification today that the World Health Organization has approved its application for an Emergency Use Listing (\"EUL\"), meaning Covaxin will now likely be accepted by a host of foreign governments, and that Indians who have received the vaccine will have fewer problems traveling overseas.\nIt's great news for Bharat, who join the likes of Pfizer / BioNTech, Johnson & Johnson (JNJ), SinoPharm, Moderna (MRNA) and AstraZeneca (AZN) on the list of EUL-approved vaccine developers - but it is not necessarily great news for Ocugen.\nVaccines on the EUL list are permitted to be sent to government's around the world as part of the COVAX scheme, designed to create equitable vaccine distribution around the world, including poorer countries, but the US is a donor to this scheme, not a beneficiary, meaning that Ocugen effectively gets no benefit, and no revenues, as a result of the WHO approval for Covaxin.\nOcugen Stock Is Already On A Downtrend - All Eyes Will Now Be On Health Canada And The FDA\nOcugen stock bounced from a price of ~$9, to a peak of ~$16 in trading today, however the share price quickly began to decline, and finished at a price of $12.7. Post-market, shares were down another 10%.\nThat reflects the fact that the WHO approval for Covaxin does little to improve Ocugen's own fortunes, and in all honesty, was something of a red herring.\nOcugen investors, and Ocugen shorts, are desperate to know what the future holds for Covaxin in the US and Canada, but they will have to wait until Health Canada and the FDA rule respectively on an Emergency Use Authorization, and an approval to begin a drastically reduced pivotal trial in the US.\nIronically, despite all of the news flow and the publication of Covaxin Phase 3 trial data, and the EUA granted to Covaxin by the Indian government, Ocugen's fortunes are in a similar place to where they were when I last covered the company - barring the US EUA opportunity.\nThat opportunity - the one that may have sent Ocugen shares through the roof - has gone, but as I argued in my last post, I think it's possible that the US would not object to stockpiling some of the Covaxin shot, which has a differentiated mechanism of action, and a shelf life of up to years if stored at 2- 8 degrees centigrade.\nCovaxin may have benefits that other vaccines do not, the reasoning may go, such as its ability to induce a Th1 response, conferring cell-mediated immunity and offering durable protection, and enhanced protection against COVID variants, which is the primary concern at the present time.\nOn the other hand, the US may now be able to obtain supply directly from Bharat via the WHO and be in a position to cut Ocugen - the middleman - out of any deal.\nThe fact of the matter is that Ocugen's opportunity with Bharat and Covaxin has always appeared to be one that required expediency of execution, in order to capitalize on a US market opportunity that's uncertain, perhaps negligible, at worst, and a potential multi-billion opportunity at best.\nNobody knows even if Ocugen will get an opportunity to market Covaxin in the US, but if it does, it will need to negotiate a tricky Phase 3 trial first, which could take us into the latter half of next year. Equally, no-one yet knows if Health Canada will approve the vaccine.\nConclusion\nTo summarise the current state of affairs, I would lean toward an approval in Canada - if Covaxin is good enough for the WHO, why would it not be good enough for Canada?\nBut how much product will Canada buy? Probably enough to create a substantial price spike for Ocugen stock, although demand is unlikely to be high enough to sustain that spike long term.\nHow much would the US buy if Covaxin was approved in the US? Again, I cannot see it being a high enough volume to catapult Ocugen's market cap above say $10bn, but if it buys any at all, Ocugen's market valuation is more or less guaranteed to surge, at least temporarily.\nIn conclusion, I would argue that there is enough intrigue and opportunity in the Ocugen story to keep investors interested - on both the short and long sides. The WHO approval does not directly benefit Ocugen revenues wise, but it's another win for Covaxin, which is in turn a win for Ocugen.\nIf I has been holding Ocugen stock since December last year, when it traded at >$0.5, frankly I would have sold by now, but if I had opened a position at ~$10, in expectation of doubling my money on a US approval, I would still be (nervously) holding.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":3859,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849574363,"gmtCreate":1635770699230,"gmtModify":1635771432150,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Just a thinker, will the masses need credit card like Mastercard Visa Amex when anyone&nbsp;can BNPL on those online&nbsp;shops? .... like like","listText":"Just a thinker, will the masses need credit card like Mastercard Visa Amex when anyone&nbsp;can BNPL on those online&nbsp;shops? .... like like","text":"Just a thinker, will the masses need credit card like Mastercard Visa Amex when anyone can BNPL on those online shops? .... like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849574363","repostId":"2179806221","repostType":4,"isVote":1,"tweetType":1,"viewCount":5359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849544133,"gmtCreate":1635770044164,"gmtModify":1635770044282,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>csuch an old time car company yet stock price is just a fraction of Tesla's, Ford need to employ dreamers management but still give dividends hor..i wish ...like like...","listText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>csuch an old time car company yet stock price is just a fraction of Tesla's, Ford need to employ dreamers management but still give dividends hor..i wish ...like like...","text":"$Ford(F)$csuch an old time car company yet stock price is just a fraction of Tesla's, Ford need to employ dreamers management but still give dividends hor..i wish ...like like...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849544133","isVote":1,"tweetType":1,"viewCount":4242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859459142,"gmtCreate":1634724598127,"gmtModify":1634724733333,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"nio niu (bullish) yah... like like","listText":"nio niu (bullish) yah... like like","text":"nio niu (bullish) yah... like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/859459142","repostId":"2176832734","repostType":4,"isVote":1,"tweetType":1,"viewCount":3085,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850104382,"gmtCreate":1634563119706,"gmtModify":1634563120160,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"very good effort writeup, but layman like me best wish is yoursuggestion what price buy ,what price sell,no obligation jus indication haha thanks,like like....","listText":"very good effort writeup, but layman like me best wish is yoursuggestion what price buy ,what price sell,no obligation jus indication haha thanks,like like....","text":"very good effort writeup, but layman like me best wish is yoursuggestion what price buy ,what price sell,no obligation jus indication haha thanks,like like....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850104382","repostId":"1127670394","repostType":4,"repost":{"id":"1127670394","kind":"news","pubTimestamp":1634561756,"share":"https://www.laohu8.com/m/news/1127670394?lang=zh_CN&edition=full","pubTime":"2021-10-18 20:55","market":"us","language":"en","title":"Is Roblox Stock Poised to Rally Soon?<blockquote>Roblox股票即将上涨吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1127670394","media":"InvestorPlace","summary":"RBLX stock is likely to be a long-term winner, but it is likely to be hurt by shorter-term hurdles f","content":"<p><div> RBLX stock is likely to be a long-term winner, but it is likely to be hurt by shorter-term hurdles first.  Roblox Corporation, which enables users to enter virtual communities, known as the metaverse ...</p><p><blockquote><div>RBLX股票可能是长期赢家，但它可能首先受到短期障碍的损害。Roblox公司，使用户能够进入虚拟社区，被称为元宇宙...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/10/is-roblox-stock-poised-to-rally-soon/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/10/is-roblox-stock-poised-to-rally-soon/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Roblox Stock Poised to Rally Soon?<blockquote>Roblox股票即将上涨吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Roblox Stock Poised to Rally Soon?<blockquote>Roblox股票即将上涨吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-10-18 20:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> RBLX stock is likely to be a long-term winner, but it is likely to be hurt by shorter-term hurdles first.  Roblox Corporation, which enables users to enter virtual communities, known as the metaverse ...</p><p><blockquote><div>RBLX股票可能是长期赢家，但它可能首先受到短期障碍的损害。Roblox公司，使用户能够进入虚拟社区，被称为元宇宙...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/10/is-roblox-stock-poised-to-rally-soon/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/10/is-roblox-stock-poised-to-rally-soon/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/10/is-roblox-stock-poised-to-rally-soon/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"source_url":"https://investorplace.com/2021/10/is-roblox-stock-poised-to-rally-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127670394","content_text":"RBLX stock is likely to be a long-term winner, but it is likely to be hurt by shorter-term hurdles first.\n\nRoblox Corporation, which enables users to enter virtual communities, known as the metaverse and create the own video games, has many positive attributes and great growth potential. What’s more, its management team appears to be adept both at making lucrative deals and adding captivating, new features to the company’s metaverse. Still, like many stay-at-home names that thrived in 2020, RBLX stock is facing important macro challenges.\nWhat’s more, despite their recent, sizeable pullback, the shares’ valuation remains quite steep. As a result of the latter two points, I’m currently cautious on the shares.\nRoblox Has Many Strengths\nRoblox has proven to be very proficient when it comes to attracting consumers to its metaverse and keeping them there. In August, thecompany reported that itsactive user base had jumped 32% from last year to 48.2 million\nMoreover, the company has been able to monetize those users fairly effectively, as it predicted that its August sales would come in at $219 million to $222 million. In 2020, Roblox’sreported revenue of $923million, way up from $508 million in 2020.\nAnd showing that it knows how to make very lucrative, highly impactful deals, Robloxannounced thatit would team up with the giant toymaker,Hasbro(NASDAQ:HAS). Under the agreement, Hasbro agreed to unveil Roblox-inspired Nerf blasters and a Monopoly board game that is based on Roblox.\nThe deal is likely to generate very high-margin royalties for Roblox that will move the needle for RBLX stock. Also worth noting is that a major cartoon creator, DreamWorks, already launched a Roblox TV series. I’m sure that Roblox is also getting high-margin royalties from that show.\nGiven the strong popularity of its metaverse, I expect the company to announce many more such deals.\nFinally, in September, the company statedthat it had added “spatial voice” that enablesvoice chat on its platform. Basically, it allows certain users to communicate with each other, using their own voices, in specified parts of Roblox’s metaverse.\nMany people like using their voices to communicate and find it very easy and natural to do so. Further, there are not very many video game developersthat have made voice chatan integral part of their offerings. Consequently, I believe that Roblox’s voice chat feature will, over the long term, make Roblox’s virtual community meaningfully more popular.\nMacro Challenges and Valuation\nAs I’ve written in multiple, past columns, video game makers, along with other developers of stay-at-home products that thrived during the heart of the pandemic, are likely to be hurt by the winding down of the virus. So it’s  unsurprising that Roblox’sdaily average users increased only4% in August versus July. That was a significant deceleration from the 8% month-over-month increase that the company reported in July compared with June.\nAs the pandemic winds down further, the company could very well report month-over-month declines in some of its user metrics, causing the shares to drop considerably. Making the stock particularly risky in the near-to-medium term is the fact that, despite its recent, steep declines, its valuation remains quite elevated.\nSince peaking in June, the stock had tumbled about 25%. Yet the shares are still changing hands for 13.5x analysts’ average 2022 revenue estimate. That’s a high valuation for a company that still generates steep losses, is in a highly competitive sector, and is facing important near-and-medium-term hurdles.\nThe Bottom Line on RBLX Stock\nRoblox appears to be well positioned to become a winner in the long term. But given its near-and-medium-term hurdles, I advise investors to wait for a better entry point before taking a bullish position in the name.","news_type":1,"symbols_score_info":{"RBLX":0.9}},"isVote":1,"tweetType":1,"viewCount":2598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850359594,"gmtCreate":1634558647174,"gmtModify":1634558864198,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"marketing power to the moon......like like","listText":"marketing power to the moon......like like","text":"marketing power to the moon......like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850359594","repostId":"1173638261","repostType":4,"isVote":1,"tweetType":1,"viewCount":834,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850350845,"gmtCreate":1634558522792,"gmtModify":1634558523172,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"$20 by New Year Day...i wish.. like like","listText":"$20 by New Year Day...i wish.. like like","text":"$20 by New Year Day...i wish.. like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850350845","repostId":"1196013286","repostType":4,"repost":{"id":"1196013286","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634555348,"share":"https://www.laohu8.com/m/news/1196013286?lang=zh_CN&edition=full","pubTime":"2021-10-18 19:09","market":"us","language":"en","title":"Ford To Invest $316M On UK EV Plant<blockquote>福特将投资3.16亿美元建设英国电动汽车工厂</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1196013286","media":"Benzinga","summary":"Ford Motor Co aims to invest up to £230 million ($316 million) to build electric car components at i","content":"<p><b><a href=\"https://laohu8.com/S/F\">Ford</a> Motor Co</b>&nbsp;aims to invest up to £230 million ($316 million) to build electric car components at its Halewood factory in northern England,&nbsp;Reuters reports.</p><p><blockquote><b><a href=\"https://laohu8.com/S/F\">福特</a>发动机公司</b>据路透社报道，该公司计划投资高达2.3亿英镑（3.16亿美元）在英格兰北部的哈尔伍德工厂生产电动汽车零部件。</blockquote></p><p> The Ford plant will produce ~250,000 power units a year from mid-2024, the first European in-house location to make electric vehicle parts for Ford, the report adds.</p><p><blockquote>报告补充说，从2024年中期开始，福特工厂每年将生产约25万辆动力装置，这是第一个为福特生产电动汽车零部件的欧洲内部工厂。</blockquote></p><p> \"This is an important step, marking Ford's first in-house investment in all-electric vehicle component manufacturing in Europe,\" Ford's Europe President Stuart Rowley said.</p><p><blockquote>福特欧洲总裁斯图尔特·罗利表示：“这是重要的一步，标志着福特在欧洲首次对全电动汽车零部件制造进行内部投资。”</blockquote></p><p> The government is contributing to the investment through its Automotive Transformation Fund.</p><p><blockquote>政府正在通过其汽车转型基金为投资做出贡献。</blockquote></p><p> Ford also has a transmission facility in Cologne, Germany. Halewood, which employs about 500 people.</p><p><blockquote>福特在德国科隆也有一家变速箱工厂。Halewood拥有约500名员工。</blockquote></p><p> <b>Price Action:</b>&nbsp;F shares closed higher by 1.23% at $15.70 on Friday.</p><p><blockquote><b>价格走势：</b>F股周五收盘上涨1.23%，至15.70美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford To Invest $316M On UK EV Plant<blockquote>福特将投资3.16亿美元建设英国电动汽车工厂</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord To Invest $316M On UK EV Plant<blockquote>福特将投资3.16亿美元建设英国电动汽车工厂</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-10-18 19:09</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/F\">Ford</a> Motor Co</b>&nbsp;aims to invest up to £230 million ($316 million) to build electric car components at its Halewood factory in northern England,&nbsp;Reuters reports.</p><p><blockquote><b><a href=\"https://laohu8.com/S/F\">福特</a>发动机公司</b>据路透社报道，该公司计划投资高达2.3亿英镑（3.16亿美元）在英格兰北部的哈尔伍德工厂生产电动汽车零部件。</blockquote></p><p> The Ford plant will produce ~250,000 power units a year from mid-2024, the first European in-house location to make electric vehicle parts for Ford, the report adds.</p><p><blockquote>报告补充说，从2024年中期开始，福特工厂每年将生产约25万辆动力装置，这是第一个为福特生产电动汽车零部件的欧洲内部工厂。</blockquote></p><p> \"This is an important step, marking Ford's first in-house investment in all-electric vehicle component manufacturing in Europe,\" Ford's Europe President Stuart Rowley said.</p><p><blockquote>福特欧洲总裁斯图尔特·罗利表示：“这是重要的一步，标志着福特在欧洲首次对全电动汽车零部件制造进行内部投资。”</blockquote></p><p> The government is contributing to the investment through its Automotive Transformation Fund.</p><p><blockquote>政府正在通过其汽车转型基金为投资做出贡献。</blockquote></p><p> Ford also has a transmission facility in Cologne, Germany. Halewood, which employs about 500 people.</p><p><blockquote>福特在德国科隆也有一家变速箱工厂。Halewood拥有约500名员工。</blockquote></p><p> <b>Price Action:</b>&nbsp;F shares closed higher by 1.23% at $15.70 on Friday.</p><p><blockquote><b>价格走势：</b>F股周五收盘上涨1.23%，至15.70美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196013286","content_text":"Ford Motor Co aims to invest up to £230 million ($316 million) to build electric car components at its Halewood factory in northern England, Reuters reports.\nThe Ford plant will produce ~250,000 power units a year from mid-2024, the first European in-house location to make electric vehicle parts for Ford, the report adds.\n\"This is an important step, marking Ford's first in-house investment in all-electric vehicle component manufacturing in Europe,\" Ford's Europe President Stuart Rowley said.\nThe government is contributing to the investment through its Automotive Transformation Fund.\nFord also has a transmission facility in Cologne, Germany. Halewood, which employs about 500 people.\nPrice Action: F shares closed higher by 1.23% at $15.70 on Friday.","news_type":1,"symbols_score_info":{"F":0.9}},"isVote":1,"tweetType":1,"viewCount":1040,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827862889,"gmtCreate":1634444122203,"gmtModify":1634444122656,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sea tsunami up up up ....like like","listText":"sea tsunami up up up ....like like","text":"sea tsunami up up up ....like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827862889","repostId":"2175112192","repostType":4,"isVote":1,"tweetType":1,"viewCount":816,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826406446,"gmtCreate":1634044956933,"gmtModify":1634044957334,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"up up like like","listText":"up up like like","text":"up up like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826406446","repostId":"1125261480","repostType":4,"repost":{"id":"1125261480","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634025975,"share":"https://www.laohu8.com/m/news/1125261480?lang=zh_CN&edition=full","pubTime":"2021-10-12 16:06","market":"us","language":"en","title":"Ocugen stock surged another 11% in premarket trading<blockquote>Ocugen股价在盘前交易中又飙升11%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125261480","media":"Tiger Newspress","summary":"Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.","content":"<p>Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.</p><p><blockquote>Ocugen股价在盘前交易中又飙升11%。该股昨日涨超8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7eb24a3fe49c219d7cca5efc7e75316a\" tg-width=\"849\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock surged another 11% in premarket trading<blockquote>Ocugen股价在盘前交易中又飙升11%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock surged another 11% in premarket trading<blockquote>Ocugen股价在盘前交易中又飙升11%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-12 16:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.</p><p><blockquote>Ocugen股价在盘前交易中又飙升11%。该股昨日涨超8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7eb24a3fe49c219d7cca5efc7e75316a\" tg-width=\"849\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125261480","content_text":"Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":975,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821947650,"gmtCreate":1633692836984,"gmtModify":1633692837369,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"will this become another CEI,i wish...like like","listText":"will this become another CEI,i wish...like like","text":"will this become another CEI,i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821947650","repostId":"1118881509","repostType":4,"repost":{"id":"1118881509","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633680221,"share":"https://www.laohu8.com/m/news/1118881509?lang=zh_CN&edition=full","pubTime":"2021-10-08 16:03","market":"us","language":"en","title":"Sundial Growers gained nearly 17% in premarket trading<blockquote>Sundial Growers在盘前交易中上涨近17%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881509","media":"Tiger Newspress","summary":"(Oct 8) Sundial Growers Inc. gained nearly 17% in premarket trading, the company buys Alcanna in C$3","content":"<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/SNDL\">Sundial Growers Inc.</a></b> gained nearly 17% in premarket trading,&nbsp;the&nbsp;company buys Alcanna in C$346M all-stock deal.</p><p><blockquote>（10月8日）<b><a href=\"https://laohu8.com/S/SNDL\">日晷种植者公司。</a></b>该公司以3.46亿加元的全股票交易收购了Alcanna，股价在盘前交易中上涨近17%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bbc0301b5f501f1d7d3629926b2f568b\" tg-width=\"1064\" tg-height=\"576\" referrerpolicy=\"no-referrer\">Alcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.</p><p><blockquote>Alcanna是加拿大最大的私营酒类零售商，经营着171家门店，主要位于艾伯塔省，但其控股子公司是加拿大大麻零售商Nova Cannabis。</blockquote></p><p> \"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.</p><p><blockquote>Sundial首席执行官扎克·乔治(Zach George)表示：“Alcanna在酒类零售领域以价值为中心的模式创造了市场稳定，我们相信在大麻领域复制这一策略具有推动类似结果的强大潜力。”</blockquote></p><p> Seeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.</p><p><blockquote>Seeking Alpha贡献者IncomeBent Investments将Sundial Growers视为投机性买入，因为加拿大大麻行业正在打造长期行业领导者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sundial Growers gained nearly 17% in premarket trading<blockquote>Sundial Growers在盘前交易中上涨近17%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSundial Growers gained nearly 17% in premarket trading<blockquote>Sundial Growers在盘前交易中上涨近17%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-08 16:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/SNDL\">Sundial Growers Inc.</a></b> gained nearly 17% in premarket trading,&nbsp;the&nbsp;company buys Alcanna in C$346M all-stock deal.</p><p><blockquote>（10月8日）<b><a href=\"https://laohu8.com/S/SNDL\">日晷种植者公司。</a></b>该公司以3.46亿加元的全股票交易收购了Alcanna，股价在盘前交易中上涨近17%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bbc0301b5f501f1d7d3629926b2f568b\" tg-width=\"1064\" tg-height=\"576\" referrerpolicy=\"no-referrer\">Alcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.</p><p><blockquote>Alcanna是加拿大最大的私营酒类零售商，经营着171家门店，主要位于艾伯塔省，但其控股子公司是加拿大大麻零售商Nova Cannabis。</blockquote></p><p> \"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.</p><p><blockquote>Sundial首席执行官扎克·乔治(Zach George)表示：“Alcanna在酒类零售领域以价值为中心的模式创造了市场稳定，我们相信在大麻领域复制这一策略具有推动类似结果的强大潜力。”</blockquote></p><p> Seeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.</p><p><blockquote>Seeking Alpha贡献者IncomeBent Investments将Sundial Growers视为投机性买入，因为加拿大大麻行业正在打造长期行业领导者。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881509","content_text":"(Oct 8) Sundial Growers Inc. gained nearly 17% in premarket trading, the company buys Alcanna in C$346M all-stock deal.\nAlcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.\n\"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.\nSeeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.","news_type":1,"symbols_score_info":{"SNDL":0.9}},"isVote":1,"tweetType":1,"viewCount":948,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865542327,"gmtCreate":1633006759932,"gmtModify":1633006760339,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","listText":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","text":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/865542327","repostId":"1194706585","repostType":2,"isVote":1,"tweetType":1,"viewCount":1446,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Yes Elon Musk is bigger than life👍😊","text":"Yes Elon Musk is bigger than life👍😊","html":"Yes Elon Musk is bigger than life👍😊"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865541223,"gmtCreate":1633006470779,"gmtModify":1633006471159,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio to the multiverse moons yeah...","listText":"Nio to the multiverse moons yeah...","text":"Nio to the multiverse moons yeah...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/865541223","repostId":"1152595089","repostType":2,"isVote":1,"tweetType":1,"viewCount":1133,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","text":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","html":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865086106,"gmtCreate":1632924013140,"gmtModify":1632924057158,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"EVery EV Evolute EVeryone&nbsp;EVentually.[财迷]&nbsp;&nbsp;","listText":"EVery EV Evolute EVeryone&nbsp;EVentually.[财迷]&nbsp;&nbsp;","text":"EVery EV Evolute EVeryone EVentually.[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/865086106","repostId":"1120133380","repostType":4,"repost":{"id":"1120133380","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632923519,"share":"https://www.laohu8.com/m/news/1120133380?lang=zh_CN&edition=full","pubTime":"2021-09-29 21:51","market":"us","language":"en","title":"Some hot EV stocks rallied in morning trading<blockquote>一些热门电动汽车股票早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1120133380","media":"Tiger Newspress","summary":"Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola and Lords","content":"<p>Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola&nbsp;and&nbsp;Lordstown&nbsp;climbed between 1% and 13%.</p><p><blockquote>一些热门电动汽车股早盘上涨。特斯拉、蔚来、小鹏汽车、理想汽车、Lucid、Nikola和Lordstown上涨1%至13%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9c1e1472c9d7e5d7c5b97601195415ed\" tg-width=\"403\" tg-height=\"422\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Wedbush expects Tesla&nbsp;have&nbsp;a&nbsp;strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.</p><p><blockquote>Wedbush预计特斯拉第三季度交付量将强劲随着电动汽车需求的加速，Musk和Co仅9月份就可能交付15万辆汽车。</blockquote></p><p> U.S. startup Lucid Group Inc&nbsp;said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.</p><p><blockquote>美国初创公司Lucid Group Inc周二表示，将于10月底开始交付续航里程超过特斯拉的豪华电动轿车。</blockquote></p><p> Lucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.</p><p><blockquote>Lucid Group首席执行官表示，该集团有望实现2022年和2023年的生产目标，并正在努力实现今年577辆汽车的目标。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some hot EV stocks rallied in morning trading<blockquote>一些热门电动汽车股票早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome hot EV stocks rallied in morning trading<blockquote>一些热门电动汽车股票早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-29 21:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola&nbsp;and&nbsp;Lordstown&nbsp;climbed between 1% and 13%.</p><p><blockquote>一些热门电动汽车股早盘上涨。特斯拉、蔚来、小鹏汽车、理想汽车、Lucid、Nikola和Lordstown上涨1%至13%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9c1e1472c9d7e5d7c5b97601195415ed\" tg-width=\"403\" tg-height=\"422\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Wedbush expects Tesla&nbsp;have&nbsp;a&nbsp;strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.</p><p><blockquote>Wedbush预计特斯拉第三季度交付量将强劲随着电动汽车需求的加速，Musk和Co仅9月份就可能交付15万辆汽车。</blockquote></p><p> U.S. startup Lucid Group Inc&nbsp;said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.</p><p><blockquote>美国初创公司Lucid Group Inc周二表示，将于10月底开始交付续航里程超过特斯拉的豪华电动轿车。</blockquote></p><p> Lucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.</p><p><blockquote>Lucid Group首席执行官表示，该集团有望实现2022年和2023年的生产目标，并正在努力实现今年577辆汽车的目标。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","LCID":"Lucid Group Inc","TSLA":"特斯拉","LI":"理想汽车","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120133380","content_text":"Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola and Lordstown climbed between 1% and 13%.\n\nWedbush expects Tesla have a strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.\nU.S. startup Lucid Group Inc said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.\nLucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.","news_type":1,"symbols_score_info":{"XPEV":0.9,"LI":0.9,"LCID":0.9,"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1068,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866535091,"gmtCreate":1632789678113,"gmtModify":1632797585127,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"reaching $15 aiming $16","listText":"reaching $15 aiming $16","text":"reaching $15 aiming $16","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/866535091","repostId":"866882541","repostType":1,"repost":{"id":866882541,"gmtCreate":1632753456483,"gmtModify":1632798074429,"author":{"id":"3568875902358937","authorId":"3568875902358937","name":"Zonnnggg","avatar":"https://static.tigerbbs.com/7f416adefcc55425b663626cd3a51516","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568875902358937","authorIdStr":"3568875902358937"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>More?","listText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>More?","text":"$Ford(F)$More?","images":[{"img":"https://static.tigerbbs.com/c187127792b60597e3826d77bcc0c479","width":"1284","height":"2778"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866882541","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":863228838,"gmtCreate":1632400543624,"gmtModify":1632800680454,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio niu (bull)ah!","listText":"Nio niu (bull)ah!","text":"Nio niu (bull)ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/863228838","repostId":"1135139549","repostType":4,"repost":{"id":"1135139549","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632386313,"share":"https://www.laohu8.com/m/news/1135139549?lang=zh_CN&edition=full","pubTime":"2021-09-23 16:38","market":"us","language":"en","title":"Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week<blockquote>蔚来表示将推迟一周发布ES8和蔚来之家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1135139549","media":"Benzinga","summary":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the openi","content":"<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p><p><blockquote>中国电动汽车制造商<b><a href=\"https://laohu8.com/S/NIO\">蔚来</a></b>正在推迟ES8 SUV的正式上市以及首家海外<b>蔚来大厦</b>据CNEVPost周三报道，挪威提前了一周。</blockquote></p><p> <b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p><p><blockquote><b>发生了什么</b>据报道，蔚来将于9月30日在挪威推出ES8，而挪威奥斯陆的第一家蔚来之家将于10月1日正式开业<b>马里乌斯·海勒</b>，蔚来挪威公司总经理。</blockquote></p><p> The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p><p><blockquote>报道没有提供任何有关延迟原因的细节。本月早些时候有报道称，这家电动汽车制造商将在挪威开设蔚来工厂，并于9月23日宣布其旗舰ES8车型的当地定价。</blockquote></p><p> Nio House is the EV maker’s concept store.</p><p><blockquote>蔚来之家是这家电动汽车制造商的概念店。</blockquote></p><p> <b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p><p><blockquote><b>为什么它很重要</b>：蔚来进入挪威标志着这家电动汽车制造商制定的雄心勃勃的海外扩张计划的第一步，该计划已在挪威取得成功<a href=\"https://laohu8.com/S/CAAS\">中国</a>作为高端电动汽车的销售商。</blockquote></p><p> NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p><p><blockquote>蔚来首席执行官<b>威廉·李</b>曾表示，如果在挪威取得成功，该公司可能会扩展到德国，然后扩展到其他欧洲国家。</blockquote></p><p> <b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p><p><blockquote><b>价格行为</b>：蔚来股价周三收盘上涨近2.3%，至35.70美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week<blockquote>蔚来表示将推迟一周发布ES8和蔚来之家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week<blockquote>蔚来表示将推迟一周发布ES8和蔚来之家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-09-23 16:38</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p><p><blockquote>中国电动汽车制造商<b><a href=\"https://laohu8.com/S/NIO\">蔚来</a></b>正在推迟ES8 SUV的正式上市以及首家海外<b>蔚来大厦</b>据CNEVPost周三报道，挪威提前了一周。</blockquote></p><p> <b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p><p><blockquote><b>发生了什么</b>据报道，蔚来将于9月30日在挪威推出ES8，而挪威奥斯陆的第一家蔚来之家将于10月1日正式开业<b>马里乌斯·海勒</b>，蔚来挪威公司总经理。</blockquote></p><p> The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p><p><blockquote>报道没有提供任何有关延迟原因的细节。本月早些时候有报道称，这家电动汽车制造商将在挪威开设蔚来工厂，并于9月23日宣布其旗舰ES8车型的当地定价。</blockquote></p><p> Nio House is the EV maker’s concept store.</p><p><blockquote>蔚来之家是这家电动汽车制造商的概念店。</blockquote></p><p> <b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p><p><blockquote><b>为什么它很重要</b>：蔚来进入挪威标志着这家电动汽车制造商制定的雄心勃勃的海外扩张计划的第一步，该计划已在挪威取得成功<a href=\"https://laohu8.com/S/CAAS\">中国</a>作为高端电动汽车的销售商。</blockquote></p><p> NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p><p><blockquote>蔚来首席执行官<b>威廉·李</b>曾表示，如果在挪威取得成功，该公司可能会扩展到德国，然后扩展到其他欧洲国家。</blockquote></p><p> <b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p><p><blockquote><b>价格行为</b>：蔚来股价周三收盘上涨近2.3%，至35.70美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135139549","content_text":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the opening of the first overseas Nio House in Norway by a week, cnEVpostreportedWednesday.\nWhat Happened: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that Marius Hayler, general manager of Nio Norway.\nThe report did not provide any details about the reasons for the delay. It was reported earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.\nNio House is the EV maker’s concept store.\nWhy It Matters:  Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in China as a seller of premium electric vehicles.\nNIO CEOWiliam Lihas said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.\nPrice Action: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":766,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":819412201,"gmtCreate":1630086512203,"gmtModify":1704955819113,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"when bitcoin rise back to $60k????","listText":"when bitcoin rise back to $60k????","text":"when bitcoin rise back to $60k????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/819412201","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://www.laohu8.com/m/news/1199074003?lang=zh_CN&edition=full","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading<blockquote>加密货币股票早盘飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p><p><blockquote>加密货币股票在早盘交易中飙升。Bit Digital、Marathon Digital、Riot Blockchain、SoS Ltd、Square、Coinbase和Paypal股价上涨1%至13%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading<blockquote>加密货币股票早盘飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading<blockquote>加密货币股票早盘飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-27 23:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p><p><blockquote>加密货币股票在早盘交易中飙升。Bit Digital、Marathon Digital、Riot Blockchain、SoS Ltd、Square、Coinbase和Paypal股价上涨1%至13%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MARA":"MARA Holdings","SOS":"SOS Limited","NCTY":"第九城市","COIN":"Coinbase Global, Inc.","RIOT":"Riot Platforms","BTBT":"Bit Digital, Inc.","CAN":"嘉楠科技","EBON":"亿邦国际"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1,"symbols_score_info":{"MARA":0.9,"COIN":0.9,"SQ":0.9,"BTCM":0.9,"EBON":0.9,"CAN":0.9,"SOS":0.9,"RIOT":0.9,"NCTY":0.9,"BTBT":0.9}},"isVote":1,"tweetType":1,"viewCount":640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":865541223,"gmtCreate":1633006470779,"gmtModify":1633006471159,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"Nio to the multiverse moons yeah...","listText":"Nio to the multiverse moons yeah...","text":"Nio to the multiverse moons yeah...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/865541223","repostId":"1152595089","repostType":2,"isVote":1,"tweetType":1,"viewCount":1133,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3559581955535845","idStr":"3559581955535845"},"content":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","text":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","html":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886746757,"gmtCreate":1631628084679,"gmtModify":1631886507380,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"still dun understand about hype on Nikola[疑问]&nbsp;","listText":"still dun understand about hype on Nikola[疑问]&nbsp;","text":"still dun understand about hype on Nikola[疑问]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/886746757","repostId":"1155175288","repostType":4,"repost":{"id":"1155175288","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631627144,"share":"https://www.laohu8.com/m/news/1155175288?lang=zh_CN&edition=full","pubTime":"2021-09-14 21:45","market":"us","language":"en","title":"EV stocks rose in morning trading<blockquote>电动汽车股早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1155175288","media":"Tiger Newspress","summary":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 0.7% and 2%.Whi","content":"<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 0.7% and 2%.While&nbsp;Lucid Group fell nearly 4%&nbsp;as&nbsp;an equity research analyst at Morgan Stanley initiated coverage of the company at underweight.</p><p><blockquote>电动汽车股早盘上涨。特斯拉、蔚来、小鹏汽车和理想汽车上涨0.7%至2%。而Lucid Group则下跌近4%，摩根士丹利股票研究分析师在跑输大盘开始对该公司进行报道。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/df9a72b93885e07dad67e2dc86b0156a\" tg-width=\"410\" tg-height=\"483\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks rose in morning trading<blockquote>电动汽车股早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks rose in morning trading<blockquote>电动汽车股早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-14 21:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 0.7% and 2%.While&nbsp;Lucid Group fell nearly 4%&nbsp;as&nbsp;an equity research analyst at Morgan Stanley initiated coverage of the company at underweight.</p><p><blockquote>电动汽车股早盘上涨。特斯拉、蔚来、小鹏汽车和理想汽车上涨0.7%至2%。而Lucid Group则下跌近4%，摩根士丹利股票研究分析师在跑输大盘开始对该公司进行报道。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/df9a72b93885e07dad67e2dc86b0156a\" tg-width=\"410\" tg-height=\"483\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","XPEV":"小鹏汽车","TSLA":"特斯拉","NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155175288","content_text":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 0.7% and 2%.While Lucid Group fell nearly 4% as an equity research analyst at Morgan Stanley initiated coverage of the company at underweight.","news_type":1,"symbols_score_info":{"XPEV":0.9,"LI":0.9,"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":803,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886336965,"gmtCreate":1631549461457,"gmtModify":1631886507393,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"ford should be a $15 share..i wish","listText":"ford should be a $15 share..i wish","text":"ford should be a $15 share..i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/886336965","repostId":"2167658404","repostType":2,"repost":{"id":"2167658404","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1631545694,"share":"https://www.laohu8.com/m/news/2167658404?lang=zh_CN&edition=full","pubTime":"2021-09-13 23:08","market":"us","language":"en","title":"Ford Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer<blockquote>福特汽车表示迈克·阿门德(Mike Amend)今天加入福特，担任新任首席数字和信息官</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2167658404","media":"T-Reuters","summary":"Ford Motor Co :Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Inform","content":"<p><html><body>Ford Motor Co <f.n>:Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer.Further Company Coverage: F.N. ((Reuters.Briefs@Thomsonreuters.Com;)).</f.n></p><p><blockquote><html><body>福特汽车公司<f.n>：福特汽车联合公司迈克·阿门德(Mike Amend)今天开始在福特担任新任首席数字和信息官。进一步的公司报道：F.N（（Reuters.Briefs@Thomsonreuters.Com；））。</f.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer<blockquote>福特汽车表示迈克·阿门德(Mike Amend)今天加入福特，担任新任首席数字和信息官</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord Motor Says Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer<blockquote>福特汽车表示迈克·阿门德(Mike Amend)今天加入福特，担任新任首席数字和信息官</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2021-09-13 23:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>Ford Motor Co <f.n>:Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer.Further Company Coverage: F.N. ((Reuters.Briefs@Thomsonreuters.Com;)).</f.n></p><p><blockquote><html><body>福特汽车公司<f.n>：福特汽车联合公司迈克·阿门德(Mike Amend)今天开始在福特担任新任首席数字和信息官。进一步的公司报道：F.N（（Reuters.Briefs@Thomsonreuters.Com；））。</f.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"III":"信息服务","DLR":"数字房地产信托公司","NGD":"New Gold","F":"福特汽车"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167658404","content_text":"Ford Motor Co :Ford Motor Co - Mike Amend Starts With Ford Today As The New Chief Digital And Information Officer.Further Company Coverage: F.N. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1,"symbols_score_info":{"F":1,"NGD":1,"DLR":1,"III":1}},"isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814358162,"gmtCreate":1630768928456,"gmtModify":1631886507448,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","text":"$NIO Inc.(NIO)$hope to reach half Tesla price haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/814358162","isVote":1,"tweetType":1,"viewCount":1048,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879786388,"gmtCreate":1636773154807,"gmtModify":1636773154970,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer the old giant ,time to wake upupup...i wish...like like","listText":"Pfizer the old giant ,time to wake upupup...i wish...like like","text":"Pfizer the old giant ,time to wake upupup...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/879786388","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2673,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":863229400,"gmtCreate":1632400374400,"gmtModify":1632800683129,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer can reach $50 by Oct....i wish","listText":"Pfizer can reach $50 by Oct....i wish","text":"Pfizer can reach $50 by Oct....i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/863229400","repostId":"1133566174","repostType":4,"repost":{"id":"1133566174","kind":"news","pubTimestamp":1632397453,"share":"https://www.laohu8.com/m/news/1133566174?lang=zh_CN&edition=full","pubTime":"2021-09-23 19:44","market":"us","language":"en","title":"Despite Vaccine Uncertainty, Pfizer Is a Buy<blockquote>尽管疫苗存在不确定性，辉瑞仍值得买入</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133566174","media":"InvestorPlace","summary":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a compan","content":"<p><div> Forget the booster shot controversy, PFE stock has better days ahead.  What would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the ...</p><p><blockquote><div>忘记加强注射的争议，PFE股票的未来会更好。如果一家公司开发了一个巨大的新产品，却没有人关心，会发生什么？对于辉瑞的投资者来说，这是...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Despite Vaccine Uncertainty, Pfizer Is a Buy<blockquote>尽管疫苗存在不确定性，辉瑞仍值得买入</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDespite Vaccine Uncertainty, Pfizer Is a Buy<blockquote>尽管疫苗存在不确定性，辉瑞仍值得买入</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-09-23 19:44</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Forget the booster shot controversy, PFE stock has better days ahead.  What would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the ...</p><p><blockquote><div>忘记加强注射的争议，PFE股票的未来会更好。如果一家公司开发了一个巨大的新产品，却没有人关心，会发生什么？对于辉瑞的投资者来说，这是...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133566174","content_text":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.\nThat finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its Q2 earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?\nVaccine Hits A Setback\nPfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated American adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.\nDespite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.\nThe idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.\nThis scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that Moderna’s(NASDAQ:MRNA) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.\nThis is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.\nBaseline Valuation Is Not That Demanding\nLet’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.\nBased on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.\nYes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.\nPFE Stock Verdict\nRight now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.\nFor longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.\nThe company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.\nIf the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":531,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869784588,"gmtCreate":1632322282944,"gmtModify":1632801226942,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","listText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","text":"Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/869784588","repostId":"1143821004","repostType":4,"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819418625,"gmtCreate":1630086116667,"gmtModify":1704955816003,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"when nio xpeng rise to$50???","listText":"when nio xpeng rise to$50???","text":"when nio xpeng rise to$50???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/819418625","repostId":"2162021329","repostType":4,"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":605437594,"gmtCreate":1639212100832,"gmtModify":1639212101161,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091708143350050","idStr":"4091708143350050"},"themes":[],"htmlText":"calm before the tsunami...i wish...like like","listText":"calm before the tsunami...i wish...like like","text":"calm before the tsunami...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605437594","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://www.laohu8.com/m/news/1133027099?lang=zh_CN&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading<blockquote>Sea Ltd股价早盘下跌超过5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p><p><blockquote>Sea Ltd股价早盘下跌超过5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading<blockquote>Sea Ltd股价早盘下跌超过5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading<blockquote>Sea Ltd股价早盘下跌超过5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-11 00:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p><p><blockquote>Sea Ltd股价早盘下跌超过5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":3159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}